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Abstract 
Salmonella and Campylobacter are two leading causes of human foodborne disease.  Cattle can 
asymptomatically shed these organisms in their feces.  Fluoroquinolones are antimicrobials used 
to treat both humans and animals. With concerns over antimicrobial resistance, antimicrobial use 
in livestock has become scrutinized. Data on prevalence and susceptibility of Salmonella and 
Campylobacter in feedlot cattle, particularly those exposed to fluoroquinolones, are sparse. The 
purpose of the research described in this dissertation was to determine the prevalence and 
quinolone susceptibility of Salmonella and Campylobacter isolated from feedlot cattle and to 
determine whether these outcomes were associated with fluoroquinolone use.  First, an 
observational study was performed at five commercial feedlots that used enrofloxacin (a 
fluoroquinolone) as first-line treatment for bovine respiratory disease (BRD). Fecal samples were 
collected from cattle pens with various levels of BRD and exposure to enrofloxacin. Salmonella 
and Campylobacter prevalence and susceptibility to quinolones, nalidixic acid and ciprofloxacin, 
were evaluated. Prevalence of Salmonella and Campylobacter was highly variable among and 
within feedlots. All but one Salmonella isolate was susceptible to nalidixic acid and 
ciprofloxacin, whereas 49% (126/256) of the Campylobacter isolates were resistant to both 
antimicrobials. However, the number of enrofloxacin treatments was not associated with the 
prevalence or susceptibilities of either organism. A second, experimental study assessed 
prevalence and quinolone susceptibilities of Salmonella and Campylobacter in feces of feedlot 
cattle administered enrofloxacin for the control of BRD (metaphylaxis). Cattle with no history of 
fluoroquinolone exposure were randomly assigned to either an enrofloxacin treated pen or a non-
treated, control pen. Cattle feces were repeatedly collected and cultured for Salmonella and 
Campylobacter, with isolates tested for susceptibilities to nalidixic acid and ciprofloxacin. 
Overall, Salmonella and Campylobacter prevalence estimates were relatively low and decreased 
over time. Resistance prevalence was negligible for Salmonella, but was high for 
Campylobacter. However, there was no evidence that enrofloxacin metaphylaxis impacted the 
prevalence of Salmonella or Campylobacter, nor did it significantly affect their susceptibility to 
human quinolones. In conclusion, enrofloxacin use in feedlot cattle does not appear to have a 
significant impact on the prevalence or resistance of Salmonella and Campylobacter.  
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Preface 
Antimicrobial resistance has become a global topic of discussion, particularly when 
antimicrobials, such as fluoroquinolones, are used to treat both human and animal diseases.  For 
over a decade, scientists have been monitoring antimicrobial resistance trends for two major 
zoonotic pathogens, Salmonella and Campylobacter, in an attempt to evaluate the use of 
antimicrobials in livestock and their impact on human health. Numerous published documents 
describing the prevalence of these two microorganisms and their susceptibility to quinolones for 
both poultry and swine are available, while prevalence estimates for beef cattle are scarce.  
The studies described in this dissertation provide pen prevalence estimates for Salmonella 
and Campylobacter, as well as quinolone susceptibility data in an effort to fill in key data gaps.  
The study described in chapter 2 was a cross-sectional observational study used to evaluate the 
prevalence and quinolone susceptibilities of Salmonella isolated from the feces of pre-harvest 
cattle that used the fluoroquinolone, enrofloxacin, to treat bovine respiratory disease. This study 
was published in the journal Foodborne Pathogens and Diseases in 2015.  The study described 
in chapter 3 is additional data collected from the study described in chapter 2, yet focuses on the 
prevalence and quinolone susceptibilities of Campylobacter.  My final study, which is discussed 
in chapter 4, evaluates the effect of enrofloxacin metaphylaxis on the prevalence and quinolone 
susceptibilities of Salmonella and Campylobacter isolated from the feces of feedlot cattle.  
Overall, the research described in this dissertation indicates that the use of enrofloxacin for the 
treatment or control of bovine respiratory disease does not significantly impact the prevalence of 
Salmonella or Campylobacter, nor does it significantly alter the susceptibility of these organisms 
to human quinolones.  
1 
Chapter 1 - Literature Review to Explore the Epidemiology of 
Salmonella and Campylobacter, their Antimicrobial Susceptibilities 
and the Use of a Fluoroquinolone in the Livestock Industry 
  
 Introduction 
 For many decades, antimicrobials have been used to treat and protect both human and 
animal populations. With the overuse and at times, inappropriate use of these antimicrobial 
agents, the emergence and transmission of antimicrobial resistance has become a global concern. 
In order to maintain a balance between keeping animals healthy and minimally impacting the 
health and well-being of our human population, we must understand what antimicrobial 
resistance is, how it develops, how it is spread, how to detect and monitor its existence and what 
data are needed to evaluate the human food safety risk when medically important antimicrobials 
are used in the livestock industry.  
 
 Antimicrobial Resistance 
 According to the Centers for Disease Control and Prevention (CDC), antimicrobial 
resistance is defined as the ability of microorganisms to resist the effects of drugs and, therefore, 
continue to grow causing untreatable infections that require expensive and sometimes toxic 
intervention (CDC, 2015a).  An antimicrobial is an agent that kills microorganisms or inhibits 
their growth (Madigan et al. 2006).  Antibiotics, which are a type of antimicrobial, were first 
discovered by Alexander Fleming in 1928 (Madigan et al. 2006). Penicillin, an antibacterial 
product of the fungus Penicillium chrysogenum, was the first clinically effective antimicrobial 
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commercially produced for the control of human staphylococcal and pneumococcal infections 
(Madigan et. al. 2006). Over the past 90 years, numerous antimicrobials have been introduced 
and mass produced to not only destroy disease-causing microorganisms in humans, but to also 
prevent, control and treat disease in animals.  With the widespread use of antimicrobials in both 
the human and animal population increasing over the years, the development of antimicrobial 
resistance has become a major threat to our global healthcare system (CDC, 2013). 
 Antimicrobial resistant bacteria and fungi cause an estimated two million illnesses and 
23,000 deaths in the United States, annually (CDC, 2015a). With penicillin-resistant 
Staphylococcus being identified as the first antimicrobial-resistant organism in 1940, resistance 
to other antimicrobials, such as tetracycline (1950), erythromycin (1953) and methicillin, soon 
followed (CDC, 2015a). Currently, resistant organisms that pose the most serious threat in the 
US are drug resistant Campylobacter, non-typhoidal Salmonella, Salmonella Typhi, Shigella, 
Streptococcus pneumonaie, Staphylococcus aureus and Mycobacterium tuberculosis, as well as 
multi-drug resistant Acinetobacter and Pseudomonas aeruginosa (CDC, 2013). These 
antimicrobial-resistant infections can require prolonged treatment, extended hospital stays and 
can cost up to $20 billion in excess direct healthcare costs (CDC, 2013). With antimicrobial use 
being one of the most important factors leading to antimicrobial resistance, judicious use of 
antimicrobials in both human and veterinary medicine is deemed necessary.  
 
 Foodborne Illness 
 Salmonella and Campylobacter, the pathogens studied in this dissertation, are considered 
two of the top five foodborne pathogens that cause human illness in the United States (Hoffmann 
et al., 2012). In 2009, the estimated annual cost of illness in the US for non-typhoidal Salmonella 
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was $3.3 million and $1.7 million for Campylobacter spp. (Hoffmann et al., 2012). In 2011, the 
CDC reported that there were an estimated 1 million illnesses, 19,000 hospitalizations and 380 
deaths reported annually due to non-typhoidal Salmonella. The estimated annual number of 
illnesses, hospitalizations and deaths reported for Campylobacter spp. was 850,000, 8,500 and 
76, respectively (CDC, 2014).   
 Salmonella and Campylobacter are shed in the feces of both beef and dairy cattle 
(Voetsch et al., 2004; Taylor et al., 2013). Human foodborne illness is often traced back to a 
food source of animal origin, such as raw (unpasteurized) milk, eggs, poultry, contaminated 
produce and undercooked meat (Taylor et al., 2013; Greig et al., 2009). Pathogenic organisms 
associated with foodborne illness can often carry antimicrobial resistance genes. Due to the use 
of antimicrobials in animal production, antimicrobial resistance has become a major concern, 
especially for those pathogenic organisms transmitted through food (Hoffmann et al., 2012). 
 
 Salmonella 
 Salmonella are Gram negative, rod-shaped facultative anaerobes with peritrichous 
flagella and inhabit the intestinal tracts of most invertebrates, including fish, reptiles, and 
mammals (Madigan et al. 2006).  Salmonella can grow in cells along the lining of the intestine, 
as well as inside macrophages that normally ingest and kill pathogenic organisms (Madigan et al. 
2006). Salmonella have several virulence factors such as enterotoxins, cytotoxins, 
lipopolysaccharide (LPS), and heat-shock proteins that allow the organism to escape the host’s 
immune system and establish itself within its environment.   
 There are over 2500 serotypes of Salmonella currently identified (CDC, 2015b). 
Salmonella serotypes Enteritidis, Typhimurium and Newport are the most prevalent serotypes 
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reported in U.S human laboratories with Enteritidis being the most common serotype reported 
(FDA, 2014). A surveillance report illustrating Salmonella isolates recovered from human 
samples from 1968-2011 indicated that Salmonella Enteritidis infections increased from 1980 to 
1995, but decreased by 30% from 1996 to 2006 (CDC, 2015b). The majority of the isolates 
recovered were from the stool samples of children ages 0-4 years and infections were the most 
prevalent during the late summer months (July-September) (CDC, 2015b).  In 2014, 2,127 
Salmonella were isolated from (U.S.) human stool samples and of the samples collected 438 
(20.6%) were serotype Enteritidis, 262 (12.3%) were serotype Typhimurium and 235 (11.0%) 
were serotype Newport (FDAa, 2016).           
Salmonella has been shown to be prevalent in cattle (Dargatz et al., 2003; Bosilevac et 
al., 2009; Haneklaus et al., 2012).  In 2009, a study evaluated the prevalence of Salmonella in 
commercially produced ground beef (Bosilevac et al., 2009). Samples from seven different 
regions of the United States were collected over a 24-month period and analyzed for the presence 
of Salmonella enterica.  A total of 4,136 samples were collected and of those samples, 172 tested 
positive for Salmonella, making the overall sample prevalence 4.2%.  Salmonella was isolated 
more often in summer months (June-Sept.) than winter months (Oct.-Dec.) and regional monthly 
prevalence of Salmonella strains varied from 1.8% to 6.5%.  The most common serotypes 
isolated were Dublin, Reading, and Typhimurium.  Multi-drug resistant (MDR) strains accounted 
for 0.6% of the overall prevalence and resistance prevalence varied by region and species 
(Bosilevac et al., 2009).  
Salmonella have been isolated from the feces, hides, and lymph nodes of cattle (Khaitsa 
et al., 2007; Kunze et al., 2008; Haneklaus et al., 2012). Salmonella fecal shedding was 
examined in North Dakota feedlot cattle during the finishing period (Oct 2003-May 2004) and 
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was found to be low at feedlot arrival (0.7%; 1/144), increased to 5.6% (8/144) 28 days later and 
increased to 62.0% (89/143) just prior to slaughter (Khaitsa et al., 2007). Salmonella enterica 
prevalence on hides and in the feces of harvest-ready cattle in the southern high plains of the 
United States was 69.6% and 30.3% (n=1,681 samples), respectively and had an average 
concentration of 1.82 log10 /100 cm2 on hides and 0.75 log10/g in the feces (Kunze et al., 2008). 
Lymph nodes were examined in cattle harvested from seven different feedlots over a three-
month period for the prevalence of Salmonella (Haneklaus et al., 2012). Salmonella prevalence 
within the lymph nodes of cattle was highly variable within feedlot and among feedlots and 
ranged from 4.0% to 88.2% (Haneklaus et al., 2012).     
A study evaluating the prevalence and antimicrobial susceptibility of Salmonella spp. 
isolated from U.S. cattle feces in 1999 and 2000 indicated that isolates were most frequently 
resistant to tetracycline (35.9%, 252/702), streptomycin (11.1%, 78/702), ampicillin (10.4%, 
73/702) and chloramphenicol (10.4%, 73/702). Multidrug resistance (isolates resistant to ≥ 2 
antimicrobials) occurred in 11.7% (82/702) of the isolates (Dargatz et al., 2003). Ground beef 
samples, collected by 18 U.S. commercial ground beef producers between July 2005 and June 
2007, were evaluated for Salmonella prevalence and antimicrobial susceptibility (Bosilevac et 
al., 2009). Results indicated that 4.2% (172/4,136) of the samples were positive for Salmonella 
and of the samples collected; the majority (21.5%, 37/172) of the isolates were resistant to 
tetracycline, chloramphenicol or ampicillin.  Serotypes Agona, Dublin, Newport, Reading and 
Typhimurium were resistant to four or more antimicrobials and only one serotype (Agona) was 
resistant to a quinolone (nalidixic acid; Bosilevac et al., 2009).    
According to the 2012-2013 National Antimicrobial Resistance Monitoring System 
(NARMS) interim surveillance report, non-typhoidal Salmonella were recovered from 0.9% 
6 
(15/1663) of the retail meat ground beef (0.9%; 15/1663) samples collected and the most 
common serotypes isolated were Montevideo (26.7%) and Dublin (26.7%; FDA, 2015b).  A 
portion of the Salmonella isolates recovered from retail beef samples were resistant to 
Ceftriaxone (26.7%; 4/15), while 46.7% (7/15) of the Salmonella isolates were susceptible to all 
drugs tested (FDA, 2015a).  The 2014 NARMS Integrated Report indicated that prevalence of 
non-typhoidal Salmonella was at an all-time low for retail ground beef (0.8%; FDA, 2016b). 
Ceftriaxone resistance for Salmonella Dublin isolated from cattle declined to 29% (9/31) in 2014 
and ciprofloxacin resistance continued to be low (< 10%) for all Salmonella isolates tested 
(FDA, 2016b).      
 
 Campylobacter 
 Campylobacter are Gram negative, curved rod to spiral shaped organisms that have polar 
flagellum and thrive in microaerophilic (5% O2 10% CO2 85% N2) conditions (Madigan et. al, 
2006). Campylobacter are able to invade colonic epithelial cells by a microtubule-dependent and 
actin filament-independent invasion mechanism. These pathogens produce cytolethal distending 
toxins (Cdt A, B, C), which cause cell elongation, swelling, and apoptosis (Dasti et. al, 2010). 
They contain lipopolysaccharide, which is involved in adherence and antigenic variation and 
some Campylobacter strains contain polysaccharide capsules, which help it escape the host’s 
immune system (Madigan et. al, 2006).   
The prevalence of Campylobacter has been characterized in both humans and animals. 
The Foodborne Diseases Active Surveillance Network (FoodNet) indicated that Campylobacter 
was a common pathogen isolated from humans and accounted for 41.7% (n=3,445) of the travel-
associated infections during 2004-2009 (Kendall et al., 2012). There are numerous 
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Campylobacter species that are responsible for human campylobacteriosis which include: C. 
jejuni, C. coli, C. fetus, C. hyointestinalis, C. upsaliensis, and C. ureolyticus (Sanad, 2011). 
Campylobacter jejuni is the most common bacterial cause of gastroenteritis and has been 
associated with both waterborne and foodborne outbreaks (Taylor et al., 2013).   
In 2009, fecal prevalence of Campylobacter species in beef cattle from seven large 
commercial feedlots in Alberta, Canada was evaluated. Out of 2,776 fresh pen-floor samples, 
87% (2420 of 2776) were culture positive for Campylobacter (Hannon et al., 2009).  The 
prevalence of Campylobacter jejuni in feedlot cattle was monitored throughout the feeding 
period and found to increase from 1.6% at first sampling to > 60% at the final sampling just prior 
to cattle harvest (Besser et al., 2005). Campylobacter isolates recovered from US feedlot cattle in 
1999 and 2000 (N=448) were examined for antimicrobial resistance and of the C. jejuni tested, 
49.1% were resistant to tetracycline, 10.2% were resistant to nalidixic acid, 8.4% were resistant 
to trimethoprim/sulfamethoxazole and 1.8% were resistant to ciprofloxacin.  Approximately 20% 
(n=88) of the isolates tested in this study were resistant to two or more antimicrobials and 6% 
(n=25) were resistant to three or more antimicrobials (Englen et al., 2005).   
According to the 2012-2013 NARMS interim surveillance report, Campylobacter was 
isolated from 42% (n=662) of the cecal samples collected from cattle (FDA 2015a). The majority 
of the isolates were C. jejuni (80.2%; 531/662), while the remaining isolates were C. coli 
(19.8%; 131/662).  Of the Campylobacter isolates tested, 12% were resistant to ciprofloxacin and 
less than 5% were resistant to erythromycin (FDA 2015a).  
The 2014 NARMS Integrated report revealed that Campylobacter prevalence in cecal 
samples collected from beef cows was similar to the prevalence reported in the 2012-2013 
integrated report (42%; FDA 2016b). Erythromycin resistance remained low for these isolates 
8 
(0.3%) and ciprofloxacin-resistance increased (16% for C. jejuni (n=531); 62% for the C. coli 
(n=131; FDA, 2016b). Recovery of Campylobacter in retail ground beef during the 2002-2007 
sampling period was low/negligible and therefore is no longer isolated or reported (FDA 2015a).   
 
 Antimicrobial Resistance Transmission 
Antimicrobial resistance is often coded by genes which are spread through a process 
called horizontal gene transfer.  Horizontal transfer of resistance genes among bacterial 
populations can occur by transduction, transformation, and conjugation (Giguere et al., 2006).  
Transduction is the transfer of DNA via a bacteriophage. The DNA is injected into a bacterial 
cell where it then becomes integrated into the chromosome of the recipient cell. Transformation 
is the uptake of naked DNA by a competent cell, so that recombination within the recipient’s 
genome can take place. Conjugation is the transfer of a plasmid from a donor cell to a recipient 
cell where it can replicate and acquire transposon-carrying antimicrobial resistance genes 
(Giguere et al., 2006). The factors associated with the rate at which antimicrobial resistance 
genes are generated and transferred are still being investigated and are often found to be 
pathogen-specific (Giguere et al., 2006).   
 Salmonella and Campylobacter, which are resistant to multiple antimicrobials, have been 
found to be associated with the spread of antimicrobial resistance (Endtz et al., 1991; McDermott 
et al., 2002; Dechet et al., 2006; Doyle et al., 2015).  A widespread outbreak of foodborne illness 
was documented in the mid-1990s in northeastern United States and was associated with 
Salmonella Typhimurium DT104.  This pathogenic organism was highly resistant to ampicillin, 
chloramphenicol, streptomycin, sulfonamides and tetracycline (ACSSUT) and is still a major 
threat to our food supply today (Dechet et al., 2006; Doyle et al., 2015).  
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 Campylobacteriosis in humans is typically traced back to poultry (FDA, 2014). 
Campylobacter coli and jejuni are typically isolated from both turkeys and chickens and have 
been found to be co-resistant to tetracycline, doxycycline, erythromycin, nalidixic acid and 
ciprofloxacin (FDA, 2015).  Fluoroquinolones sarafloxacin and enrofloxacin, approved for 
controlling E. coli infections in poultry, were removed from the market in the early 2000s. 
Surveillance data suggested that there was a temporal association between the approval/use of 
these drugs in poultry and the increased resistance in Campylobacter isolates recovered from 
human infections (Endtz et al., 1991; McDermott et al., 2002). Low levels of resistance to 
human quinolones (nalidixic acid and ciprofloxacin) are reported still today in both chicken and 
turkey, even after the removal of these products from the market (FDA, 2015).  
 Enrofloxacin (Baytril 100®), which is a broad spectrum antimicrobial manufactured by 
Bayer Animal Health, is approved in the U.S. for the treatment and control of bovine respiratory 
disease in beef cattle. Though resistance to human quinolones remains low for retail meat 
products, fluoroquinolone use in livestock continues to be highly scrutinized (Smith and 
Fratamico, 2010; Marshall and Levy, 2011).     
 
 Fluoroquinolones and Mechanisms of Drug Resistance 
 Fluoroquinolones are currently used to treat both campybacteriosis in humans as well as 
illnesses, such as respiratory disease, in food animals. DNA gyrase and topoisomerase IV are 
two enzymes targeted by fluoroquinolones to inhibit DNA syntheses in pathogenic bacteria 
(Hooper, 2001). These two enzymes are structurally related to one another showing homology in 
gyrA and gyrB subunits of DNA gyrase and ParC and ParE subunits of topoisomerase IV.  Both 
DNA gyrase and topoisomerase IV act by breaking DNA strands apart, passing another segment 
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through the break, and then resealing the break. Fluoroquinolones have been shown to trap the 
enzymes during the topoisomerization reaction preventing movement of the replication fork, thus 
inhibiting protein synthesis. These trapped complexes trigger other unfavorable events, which 
eventually result in cell death (Hooper, 2001).   
 Mechanisms of quinolone resistance used by pathogenic microorganisms, such as 
Salmonella and Campylobacter, have been shown to include alterations in target enzymes (DNA 
gyrase and/or topoisomerase IV), alterations in drug permeation and the use of active efflux 
pumps (Giguere et al., 2006; Jesse et al., 2006; Chen et al., 2007).  Acquisition of a broad-
spectrum mechanism, such as the multi-drug efflux pump system, or multiple mechanisms 
acquired simultaneously, can lead to multiple drug resistance (Chen et al., 2007).  Studies have 
shown that resistance mechanisms used by Salmonella and Campylobacter can cause decreased 
susceptibility to fluoroquinolones. Multidrug resistance efflux pumps and mutations in 
topoisomerase genes among naturally occurring fluoroquinolone-resistant Salmonella enterica 
serovar Typhimurium strains were examined by scientists and found that deletions in efflux 
pump genes (acrAB and tolC) increased fluoroquinolone susceptibility four-fold (Chen et al., 
2007). These gene deletions, along with the replacement of gyrA with wild-type gyrA, increased 
susceptibility to fluoroquinolones greater than 500-fold.  These data show that the acquisition of 
efflux pumps, in combination with topoisomerase gene mutations, play an important role in the 
development of fluoroquinolone resistance (Chen et al., 2007).  
 Another study showed that the overexpression of ramA in a susceptible strain of 
Salmonella increased expression of the AcrAB efflux pump (Abouzeed et al., 2008). Inactivation 
of a regulatory protein (ramR) upstream from ramA resulted in a four-fold increase in the 
minimum inhibitory concentration (MICs) results for nalidixic acid, flumequine, enrofloxacin, 
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ciprofloxacin, chloramphenicol, florfenicol, and tetracycline. This inactivation also resulted in 
four-fold increase in ramA gene expression and AcrAB efflux pump expression.  This suggests 
that ramR plays a major role in the up regulation of the ramA and AcrAB genes, which are both 
responsible for multidrug resistance in Salmonella enterica serovar Typhimurium (Abouzeed et 
al., 2008). 
 Campylobacter coli and Campylobacter jejuni isolates recovered from chicken and beef 
cattle, with distinct mutations in gyrA (Thr86Ile and Thr86Ala), have been shown to be resistant 
to both ciprofloxacin and nalidixic acid (Jesse, et al., 2006). Minihan and others investigated the 
role of the Thr-86-Ile mutation in the gyrA gene and explored the involvement of the CmeABC 
efflux system in multi-drug resistant C. jejuni isolates (Minihan et al., 2006). Out of the 33 
isolates tested, only five (15%) of the ciprofloxacin-resistant C. jejuni isolates were found to 
have the Thr-86-Ile point mutation and zero isolates had the efflux pump genes (CmeB or 
CmeR) present.  Scientists have previously reported that both Thr-86-Ile point mutations and 
CmeABC efflux system are predominant mechanisms for ciprofloxacin resistance. However, 
because only the point mutation was present in the majority of the multi-drug resistant 
Campylobacter isolates tested for this study, authors concluded that further research is needed to 
identify the mechanisms of resistance associated with multi-drug resistant Campylobacter 
(Minihan et al., 2006). 
 
 Transmission of Fluoroquinolone Resistance 
 Fluoroquinolone resistance determinants have been shown to be acquired through 
horizontal gene transfer (Luangtongkum, et al, 2009). Horizontal gene transfer is mediated by 
transformation and transduction for both Salmonella and Campylobacter. As mentioned above, 
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transformation is the uptake of naked DNA by a competent cell, while transduction is the transfer 
of DNA via a bacteriophage. The most common method of horizontal gene transfer in enteric 
organisms, specifically Campylobacter, is via natural transformation (Luangtongkum, et al, 
2009).  Plasmids, which are circular chromosomal DNA that can replicate independently within 
a cell, are another way bacteria transfer resistance genes from one organism to the next (Tran and 
Jacoby, 2002). The plasmid pMG252 was discovered in a clinical strain of Klebsiella pneumonia 
in the U.S. in 1994 and contained the qnr gene responsible for quinolone resistance (Jacoby et 
al., 2003). Though plasmid-mediated quinolone resistance is often rare, isolates containing this 
plasmid were highly resistant to quinolones, as well as ampicillin (AmpC) and beta lactams 
(FOX-5 β-lactamase) (Jacoby et al., 2003).  
 Animals harboring enteric species such as Salmonella and Campylobacter have been 
found to be significant reservoirs for the transfer of resistance genes to humans and other animals 
(Sippy et al., 2012). Specifically, small mammals and birds, as well as insects have been shown 
to play a significant role in the transmission of quinolone-resistant Campylobacter to livestock 
(Sippy et al., 2012; Zurek et al., 2014). Commensal microflora, primarily from the 
gastrointestinal tract of humans and animals, along with soil microbiota, has been found to 
harbor antimicrobial resistance genes (Boerlin and Reid-Smith, 2008). Cattle, poultry and swine 
feces harbor antimicrobial resistance genes, which may spread to humans by the consumption of 
contaminated food (Endtz et al., 1991; Englen et al., 2005; Khaitsa et al., 2007; Tadesse et al., 
2011).  Another potential source of transmission of multidrug-resistance is through contact with 
family pets (Acke, 2009).  Campylobacter jejuni isolates (n=51) obtained from 179 dogs and cats 
in Ireland were found to be resistant to nalidixic acid (37.3%), ciprofloxacin (19.6%), 
tetracycline (13.7%), ampicillin (13.7%), erythromycin (11.8%) and chloramphenicol (5.9%).  
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Resistance to two or more antimicrobials was detected in 31.4% of the Campylobacter jejuni 
isolates recovered, which illustrates the importance of proper hygiene in households that 
contained pets (Acke, 2009).   
 Studies have also shown that antimicrobial resistance can be present and transmitted even 
in the absence of antimicrobial selection pressure. Fecal (n=838) and carcass (n=1173) samples 
from both conventional and antimicrobial-free (ABF) swine production farms were collected and 
examined for the presence of Campylobacter. The minimum inhibitory concentration (MIC) of 
each sample was determined and results indicated that 3.7% and 1.2% of the Campylobacter coli 
isolates collected from both conventional and ABF swine, respectively, were resistant to 
ciprofloxacin (Tadesse et al, 2011). A similar phenomenon was seen when “specific pathogen-
free” chickens were colonized with fluoroquinolone- resistant Campylobacter in an environment 
free of antimicrobials (Luo et al., 2004). Chickens shed Campylobacter in their feces at 
concentrations ranging from 105 to 108 cfu/g and by the end of the experiment all isolates 
recovered had genomic DNA similar to that of the resistant (challenge) isolate. Even without 
antimicrobial selection pressure, isolates failed to lose their gyrA mutations and associated 
fluoroquinolone resistance (Luo et al., 2004).      
 
 Surveillance and Detection 
 The National Antimicrobial Monitoring System (NARMS) was established in 1996 as a 
national public surveillance system to track changes in antimicrobial resistance in human, retail 
meat, animal and environmental samples (FDA, 2015).  NARMS is a collaborative effort among 
state and local public health departments, the Centers for Disease Control (CDC), the U.S. Food 
and Drug Administration (FDA) and the U.S. Department of Agriculture (USDA) (CDC, 2015a).  
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NARMS, the Foodborne Diseases Active Surveillance Network (FoodNet) and the National 
Animal Health Monitoring System (NAHMS) are all active participants in helping to better 
understand antimicrobial resistance.     
 A variety of test methods have been developed to assist in evaluating antimicrobial 
susceptibility. In vitro methods that are currently being used include: the disk diffusion assay, the 
micro broth dilution assay, the agar dilution assay and the mismatch amplification mutation 
assay (MAMA) (Giguere et al., 2006, Zirnstein et al., 1999).  The disk diffusion assay is the 
susceptibility assay most widely used by scientists and clinicians (Giguere et al., 2006).  This 
assay is cost effective and allows for numerous drugs to be tested at once.  A commercially 
prepared disk containing the antimicrobial agent of choice is placed on the surface of the agar 
which is inoculated with approximately 2x108 CFU/ml of pure culture. As growth of the bacteria 
occurs, the diffusion of the drug spreads across the media.  When the concentration of the drug 
becomes too diluted to inhibit bacterial growth, a zone of inhibition is formed.  The larger the 
zone of inhibition, the larger the concentration of drug required to inhibit pathogenic growth 
(Giguere et al., 2006).   
 The micro broth dilution assay is another susceptibility test that is comprised of micro 
titer trays that contain several antimicrobial agents of known potency in progressive two-fold 
dilutions.  The microorganism of interest is transferred to the micro titer tray, so that 
approximately 5x104 CFU/ml is suspended into each well. The tray is incubated overnight and 
the minimum inhibitory concentration (MIC) is determined by the lowest concentration of 
antimicrobial agent that completely inhibits growth of the organism in the well (Giguere et al., 
2006). Sensititre™ (TREK Diagnostic Systems) is an automated version of the microbroth 
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dilution assay and is a fast, efficient way of testing susceptibility to multiple antimicrobials in 
one micro titer tray.   
 The agar dilution assay is similar to the micro broth dilution assay, except varying 
concentrations of the antimicrobial agent, in two-fold dilutions, are added to the agar medium.  
Bacterial inoculum (~5x108 CFU/ml) is added to the surface of the agar and once all plates are 
incubated, the plate that contains the lowest concentration of antimicrobial agent to inhibit 
growth is considered the MIC for the isolate tested (Giguere et al., 2006).  
 A mismatch amplification mutation assay (MAMA), which was developed to investigate 
the type and frequency of gyrA mutations in ciprofloxacin-resistant C. jejuni isolates, is yet 
another way of confirming antimicrobial resistance (Zirnstein et al., 1999). Chromosomal DNA 
that contains the mutated genes from a resistant isolate are amplified using polymerase chain 
reaction (PCR) and primers are chosen using GenBank®.  PCR products are visualized using 
electrophoresis and the bands (or lack thereof) are compared to the wild-type strain to identify 
mutated genes (Zirnstein et al., 1999).     
 Data Gaps  
 Data generated by organizations all over the world have helped to evaluate antimicrobial 
resistance trends for human pathogenic organisms.  These data are not only used to assist in 
investigating foodborne illness outbreaks, but are also used to help evaluate the human food 
safety risk associated with the use of antimicrobials in food animals. 
 Data necessary to generate valid and informative human food safety risk assessment 
models, however, are often lacking, leaving potentially overly conservative parameters to be 
used in the model; specifically data regarding the prevalence of Salmonella and Campylobacter 
and their susceptibility to human quinolones in relation to the use of a fluoroquinolone in the 
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feedlot industry. Research designed to determine the prevalence and susceptibility of these 
organisms at different time points during feedlot production, in pens of cattle with various levels 
of BRD morbidity and in pens of cattle with different levels of exposure to a fluoroquinolone 
would assist in filling in these data gaps. Data generated from these studies would not only assist 
in estimating the human food safety risk of consuming quinolone-resistant bacteria, but would 
also help to evaluate the epidemiology of Salmonella and Campylobacter isolated from cattle 
administered a fluoroquinolone for the treatment and control of bovine respiratory disease.            
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 Abstract 
 Salmonella is an important foodborne pathogen and antimicrobial resistance can be a 
human health concern.  The objectives of this cross-sectional study were to 1) determine the 
prevalence and quinolone susceptibility of Salmonella in feces of pre-harvest commercial feedlot 
cattle, and 2) determine if the prevalence and susceptibility of Salmonella isolates were 
associated with previous fluoroquinolone use within pens.  Five feedlots in western Kansas and 
Texas were selected based on their use of a commercially licensed fluoroquinolone for initial 
treatment of bovine respiratory disease (BRD).  Twenty pen-floor fecal samples were collected 
from each of ten pens from each feedlot during early summer of 2012. Salmonella isolation was 
performed and microbroth dilution was used to determine susceptibility of isolates to nalidixic 
acid and ciprofloxacin.  Prior antimicrobial treatment data were retrieved from feedlots’ 
operational data. Generalized linear mixed models were used to assess associations between 
Salmonella prevalence and the number of fluoroquinolone treatments within pens, while taking 
into consideration cattle demographic and management factors, as well as the hierarchical 
structure of the data.  Overall cumulative fecal prevalence of Salmonella was 38.0% (380/1,000), 
but prevalence varied significantly (P < 0.01) among the five feedlots: 0.5%; (1/200), 17.5%; 
(35/200), 37.0%; (74/200), 58.5%; (117/200), and 76.5%; (153/200). Salmonella serogroups 
included C1 (49.3%), E (36.4%), C2 (13.8%), and D (0.6%). There was no significant 
association (P = 0.52) between Salmonella prevalence and the frequency of fluoroquinolone 
treatments within a pen.  All Salmonella isolates (n = 380) were susceptible to ciprofloxacin, 
while one isolate exceeded the human breakpoint [≥ 32 µg/mL] for nalidixic acid.  In conclusion, 
Salmonella fecal prevalence in pre-harvest cattle was highly variable among feedlots.  Nearly all 
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Salmonella isolates were susceptible to quinolones despite the fact that a fluoroquinolone was 
used as the primary therapeutic antimicrobial to treat BRD in these feedlot populations.   
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 Introduction 
 The Center for Disease Control and Prevention (CDC) reports that Salmonella is one of 
the leading causes of foodborne illnesses in the United States (CDC, 2012).  Salmonella 
outbreaks usually occur due to the consumption of contaminated food, water, and raw milk 
(CDC, 2012).  Though beef is not generally considered a primary source of human 
salmonellosis, feedlot cattle can be asymptomatic carriers of Salmonella and shed these bacteria 
in their feces (Fedorka-Cray et al., 1998; Dargatz et al., 2003; Dodd et al., 2011). In addition, the 
recovery of Salmonella from lymph nodes in beef carcasses has become a significant concern for 
the U.S. beef industry (Arthur et al., 2008; Haneklaus et al., 2012; Gragg et al., 2013).  The 
average prevalence of Salmonella in feces of feedlot cattle and beef cows in the U.S is generally 
low, but it can vary tremendously both within and among feedlots or herds (Fedorka-Cray et al., 
1998; Dargatz et al., 2000; Dargatz et al., 2003; Dodd et al., 2011). 
 Antimicrobials are effectively used to treat and control diseases in feedlot cattle. Some 
classes of antimicrobials, such as quinolones, are used to treat bovine respiratory disease (BRD) 
in cattle as well as foodborne illnesses in humans. With the growing concern over antimicrobial 
resistance, the use of antimicrobial drugs in livestock is highly scrutinized (Emmerson et al., 
2003; Page et al., 2012). Risk assessments are often used to evaluate antimicrobial use in 
livestock and its risk to humans; however, data necessary to develop valid and informative 
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quantitative risk assessment models are often lacking.  Current knowledge regarding the 
prevalence of Salmonella in U.S. beef cattle and their antimicrobial susceptibilities, particularly 
to fluoroquinolones, is limited.   National studies of feedlots and beef cows have shown that 
resistance of Salmonella to fluoroquinolones is extremely rare, but may cluster within a few 
herds for reasons not fully defined (Fedorka-Cray et al., 1998; Dargatz et al., 2000; Dargatz et 
al., 2003; Dodd et al., 2011). The objectives of this study were to 1) determine the prevalence 
and quinolone susceptibility of Salmonella in feces from pre-harvest pens of commercial feedlot 
cattle and to 2) determine if the prevalence and susceptibility of Salmonella in fecal isolates 
differ among feedlots or among pens with different fluoroquinolone treatment histories.   
 
 Materials and Methods 
  Study Population 
 A convenience sample of five commercial feedlots in western Kansas and Texas that 
used a fluoroquinolone (Baytril 100® (enrofloxacin), Bayer HealthCare LLC, Animal Health, 
Shawnee Mission, KS) as first-line therapy for the treatment of BRD were selected for this 
research.  Feedlots were selected based on previous fluoroquinolone use and their willingness to 
participate in our study.  Ten study pens within each feedlot were selected in consultation with 
feedlot managers based on the pens’ projected slaughter dates, allowing for pens with both high 
and low respiratory disease morbidity (thus antimicrobial use), to be selected when available.  
Health and treatment data on study pens, including the number of animals treated with a 
fluoroquinolone or any other antimicrobials, were retrieved from the feedlots’ operational 
database.  
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 Twenty, freshly voided fecal samples were collected from the pen floors of each of the 
ten pens of cattle (approximately 1-2 weeks prior to slaughter) within each feedlot (total samples 
per feedlot =200) during May-July 2012. Cattle fecal samples were collected using plastic 
spoons and were placed in Whirlpak bags (Nasco, Inc., Fort Atkinson, WI).  The samples were 
then transported on ice to the Kansas State University (KSU) Pre-harvest Food Safety laboratory 
for isolation of Salmonella.  
 
   Isolation of Salmonella  
 Ten grams of feces from each sample was placed in 90 mL Tetrathionate (TT) broth 
(Becton-Dickinson, Sparks, MD) and incubated for 24 h at 37°C.  From the TT broth, 100 µL of 
the inoculum was transferred to 10 mL Rapport-Vassiliadis broth (Becton-Dickinson) and 
incubated at 42°C for 24 h. The enriched sample was then streaked for isolation on Hektoen 
Enteric (HE) agar plates (Becton-Dickinson) and incubated at 37°C for 24 h.  Three presumptive 
colonies with morphology consistent with Salmonella (blue-green colony with black center) 
were streaked onto blood agar (Remel, Lenexa, KS) and incubated at 37°C for 24 h. Isolates 
were subjected to slide agglutination with the Salmonella polyvalent O antisera for Salmonella 
serogroups B, C1, C2, D1, D2, and E. Isolates were considered Salmonella based on hydrogen 
sulfide production on HE agar and agglutination with the polyvalent O antisera.   These isolates 
were stored in cryo-protection beads (Hardy Diagnostics, Santa Maria, CA) at -80°C until further 
tested. Serotyping of isolates found to be resistant based on microbroth dilution methods 
(described below) was performed by the National Veterinary Services Laboratory (Ames, IA).  
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  Susceptibility testing 
 Minimum inhibitory concentrations of ciprofloxacin and nalidixic acid were determined 
for each isolate by micro-broth dilution method (CLSI, 2008) using human Salmonella 
breakpoints (CLSI, 2010).  Stock solutions of ciprofloxacin and nalidixic acid (Sigma-Aldrich, 
St. Louis, MO) were prepared in sterile, distilled water at a concentration of 1 mg/mL based on 
the potency of the antibiotic. Nalidixic acid was tested at concentrations of 100, 50, 25, 12.5, 
6.25, 3.125, 1.56, 0.78, 0.39 and 0.195 µg/mL and ciprofloxacin was tested at concentrations of 
3.125, 1.56, 0.78, 0.39, 0.195, 0.098, 0.024, 0.012, and 0.006 µg/mL. For the preparation of the 
inoculum, a single colony picked from a plate was inoculated into 10 mL Mueller Hinton II broth 
(Becton- Dickinson) and incubated for 6 h and the cell turbidity was adjusted using the 0.5 
McFarland turbidity standard.  The antimicrobial susceptibilities were performed in 96-well 
microtiter plates (Becton-Dickinson). Plates were incubated at 37° C for 24 h and results were 
recorded as growth or no growth within each well.   
 This process was performed separately for each antibiotic (ciprofloxacin and nalidixic 
acid) and each Salmonella isolate was tested in quadruplicate. Quality control organism, 
Escherichia coli (ATCC 25922), was used to ensure validity of the test.  The minimum 
inhibitory concentration (MIC) was determined by the lowest concentration of antimicrobial 
agent that completely inhibited the growth of the organism. Salmonella isolates were considered 
susceptible to nalidixic acid and ciprofloxacin, if the MIC was ≤ 16 µg/mL and ≤ 1 µg/mL, 
respectively and considered resistant if the MIC was ≥ 32 µg/mL and ≥ 4 µg/mL, respectively 
(CLSI, 2010).  Isolates considered resistant were tested for susceptibility using Sensititre® plates 
that contained 17 antimicrobial drugs and a semi-automated testing system (Sensititre; TREK 
Diagnostics, Westlake, OH).  
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 Statistical Analysis 
Associations between antibiotic use and demographic characteristics with Salmonella 
pen-level prevalence were evaluated using generalized linear mixed models which were fitted 
using a binomial distribution, maximum likelihood estimation, complimentary-log-log link, 
Kenward-Roger degrees of freedom and Newton-Raphson and Ridging optimization procedures 
(Proc GLIMMIX SAS 9.3, SAS Institute, Inc., Cary, NC). A random intercept for feedlot was 
included to account for the clustering effect of pens nested within feedlots. Overdispersion was 
adjusted for by including a multiplicative parameter (scale parameter).  
The outcome variable was the number of Salmonella positive samples in a pen 
(events)/number of samples collected per pen (trials). Independent variables included the number 
of BRD fluoroquinolone treatments administered, body weight at arrival, days on feed, sex 
(steers/heifers), and antimicrobial metaphylaxis use in the pen (use/no use).  Due to the 
variability in pen size, the variable pertaining to the number of fluoroquinolone treatments was 
coded as the number of treatments per 100 cattle. All continuous variables (number of 
fluoroquinolone treatments per 100 cattle, body weight and days on feed) were categorized in 
quartiles to avoid violation of the linearity assumption. 
Pearson’s and Spearman’s correlation analyses were performed to identify highly 
correlated variables (≥ |0.80|) prior to initiating a multivariable model building process. Initially, 
variables unconditionally associated with the outcome in the univariable screen (P < 0.40) were 
included in the main effects model.  The number of fluoroquinolone treatments per 100 cattle, 
considered our exposure variable of interest, was forced in our multivariable model regardless of 
its significance.  The following variables, considered a priori confounders were tested: sex, 
metaphylaxis use, and body weight: if their removal caused a 20% or greater change in the 
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coefficient of significant variables, they were considered analytical confounders and were kept in 
the model. Two-way interactions between potential a priori confounders that were deemed 
significant at the 5% level (P < 0.05) were kept in the model. Following forward selection, non-
significant variables (P > 0.05), that were not acting as confounders or effect modifiers were 
removed from the multivariable model. Furthermore, to evaluate whether the within-pen 
prevalence of Salmonella differed among feedlots, feedlot was included as a fixed effect in a 
logistic regression model. Residual diagnostics included the evaluation of the best linearized 
unbiased predictors for feedlot-level residuals and Pearson and Deviance residuals for 
observations at the pen-level.  
Descriptive statistics were used to evaluate the MIC data for both nalidixic acid and 
ciprofloxacin for samples collected within each pen across the five feedlots.  Since each 
Salmonella isolate was tested in quadruplicate, the mode MIC value was reported for each 
sample. When only two MIC values were available and the mode could not be computed, the 
MIC value with the highest concentration was used.  If four different MIC values were reported, 
the isolate was re-tested and either the mode or the highest MIC value was reported. 
 
 Results 
  Cattle Demographics 
 The mean number of cattle per pen and the mean number of days on feed for cattle across 
all feedlots are shown in Table 1.  The mean body weight of cattle in study pens upon arrival at 
the feedlot ranged from 289 kg to 317 kg across all five feedlots.  The majority (56.0%; 28/50) of 
the cattle pens was composed of steers and one pen contained both steers and heifers.  The 
frequency of fluoroquinolone treatments across all feedlots ranged from 5 to 23 treatments 
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within a pen (Table 1). All feedlots had at least one pen where all cattle were treated 
metaphylactically for bovine respiratory disease with a range of 2 to 10 study pens receiving 
metaphylaxis (Table 1).  
  Salmonella Prevalence and Susceptibility Results 
 Overall sample-level prevalence of Salmonella across all feedlots and pens was 38.0% 
(380/1,000). Sample-level prevalence ranged from 0.5% (1/200) to 76.5% (153/200) across all 
pens within feedlots and ranged from 0.0% (0/20) to 100.0% (20/20) within pens.  The 
prevalence of Salmonella varied significantly (P < 0.01) among the five feedlots (Table 2). The 
most common Salmonella serogroups isolated from pen-floor fecal samples across the five 
commercial feedlots were C1 (49.3%; 179/363), followed by E (36.4%; 132/363), C2 (13.8%; 
50/363), and D (0.6%; 2/363) (Table 2).  Of the 380 isolates tested, 17 did not test positive for 
any of the six serogroups evaluated.   
 Potential associations between pen-level Salmonella prevalence and the number of 
fluoroquinolone treatments per 100 cattle, sex, metaphylaxis use, arrival body weight, and days 
on feed were evaluated and these data are shown in Table 3.  No significant unconditional 
associations were identified, except for arrival body weight (P = 0.02; Table 3).  The variable 
pertaining to the number of fluoroquinolone treatments per 100 cattle was not statistically 
significant (P = 0.52), but was forced in the multivariable model as it was considered our main 
variable of interest.  The multivariable model included body weight and fluoroquinolone 
treatments and provided very similar results to the univariable model results (data not shown).  
Arrival body weight was the only variable significantly associated with Salmonella prevalence 
(P = 0.02).  Pens of cattle that weighed 266 to 298 kg at arrival had significantly lower 
prevalence of Salmonella (15.5%; 95% CI = 2.4 to 70.0) than those that weighed 215 to 265 kg 
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(28.4%; 95% CI = 4.7 to 90.4; P = 0.01) or 320 to 382 kg (32.3%; 95% CI = 5.5 to 93.4; P < 
0.01).  No other differences were found among other weight categories.   
 Out of the 380 isolates tested for susceptibility to nalidixic acid and ciprofloxacin, only 
one isolate (1/380; 0.3%) was resistant (MIC ≥32 µg/mL) to nalidixic acid and all isolates were 
susceptible (MIC ≤ 1 µg/mL) to ciprofloxacin (380/380; 100.0%). As indicated previously, 
further testing was only performed on the resistant isolate, which was found to be pan susceptible 
to: Amoxicillin/Clavulanic Acid, Ampicillin, Azithromycin, Ceftiofur, Ceftriaxone, 
Chloramphenicol, Ciprofloxacin, Doxycycline, Gentamicin, Kanamycin, Minocycline, 
Streptomycin, Sulfisoxazole, Tetracycline, and Trimethoprim/Sulphamethoxazole.  Most of the 
isolates (81.6%; 310/380) had a MIC value for nalidixic acid of 6.25 µg/mL. However, some 
isolates had nalidixic acid MIC values of 1.56 µg/mL (n=1), 3.125 µg/mL (n=64), 12.5 µg/mL 
(n=3), 25 µg/mL (n=1) and > 32 µg/mL (n=1).   The majority (83.2%; 316/380) of the 
Salmonella isolates had a MIC value for ciprofloxacin of0.012 µg/mL. Whereas other isolates 
had MIC values of ≤ 0.006 µg/mL (n=31), 0.024 µg/mL (n=31), 0.098 µg/mL (n=1) and 0.39 
µg/mL (n=1).    
 
 Discussion  
 The results of our study indicated that the overall prevalence of Salmonella in feedlot 
cattle feces prior to harvest was highly variable across the five feedlots (0.5 to 76.5%) and across 
pens within feedlot (0 to 100.0%).  These data are consistent with previously reported 
Salmonella prevalence data obtained from commercial feedlot cattle (Dargatz et al., 2000; Alam 
et al., 2009; Dodd et al., 2011).   Salmonella isolates recovered from pens of cattle that were 
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treated with fluoroquinolones were susceptible to both nalidixic acid and ciprofloxacin, 
regardless of the number of fluoroquinolone treatments administered to the cattle within pens.   
 There are numerous factors that have been shown to be associated with Salmonella 
prevalence in feedlot cattle including: geographic location, season, environmental stress, number 
of days in the feedlot, and diet (Losinger et al., 1997; Barham et al., 2002; Dargatz et al., 2003; 
Edrington et al., 2010; Dodd et al., 2011).   In the current study, the Salmonella prevalence 
varied tremendously among feedlots, with the highest sample-level prevalence (76.5%) in a 
Texas feedlot and the lowest prevalence (0.5%) in a western Kansas feedlot.  Having lower 
prevalence in the most northern region is consistent with the literature (Dargatz et al., 2003; 
Green et al., 2010); however, there were too few feedlots (5) to determine potential feedlot-level 
risk factors as this was not a primary objective of this current study.     
 At the pen-level, it is important to note that the number of fluoroquinolone treatments per 
100 cattle, the number of days the cattle were in the feedlot, metaphylaxis use (whole pen use of 
an antimicrobial to control respiratory disease), and sex were not found to be associated with 
Salmonella prevalence within pens.  However, there was a significant association between cattle 
body weight at feedlot arrival and Salmonella prevalence within pens.  Specifically, pens of 
cattle with a mean weight range of 266 to 298 kg had a significantly lower Salmonella 
prevalence than the smallest body weight category (215 to 265 kg) and the heaviest body weight 
category (320 to 382 kg).  Cattle that are lighter at feedlot arrival generally require a longer 
feeding period and may have increased morbidity due to higher probability of stress, suboptimal 
immunity, and exposure to pathogens in the feedlot environment (Losinger et al., 1997; Fedorka-
Cray et al., 1998; Bancock et al., 2010,). Heavier cattle in our study, spent fewer days on feed, 
received fewer antimicrobial treatments, and had fewer pens given metaphylaxis.  However, the 
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mean prevalence of Salmonella was approximately 30% for both the lightest and heaviest weight 
categories.   A previous study evaluating Salmonella in 30 commercial feedlot cattle cohorts 
found that mean body weight at feedlot arrival was not associated with pre-harvest fecal 
prevalence of Salmonella (Dodd et al., 2011), so it seems that cattle body weight at feedlot entry 
is not a consistent predictor of Salmonella prevalence at harvest.    
 Despite the fact that all five feedlots used a fluoroquinolone as the primary line of 
therapy for the treatment of BRD (the only legal indication for fluoroquinolone use at the time of 
the study), nearly all of the Salmonella isolated for this study (379/380) were susceptible to both 
nalidixic acid and ciprofloxacin, with only one isolate found to be resistant to nalidixic acid. 
These results are consistent with previous studies demonstrating an extremely low prevalence of 
quinolone-resistant Salmonella isolated from feedlot cattle (Beach et al., 2002; Sorensen et al., 
2002; Edrington et al., 2010).  However, the results reported here are unique as this is the first 
study in which the use of fluoroquinolones was an inclusion criterion to select feedlots for the 
study population.   
Several studies completed over the last decade have shown that less than 1.0% of the 
Salmonella isolates recovered from cattle feces, hides and carcasses have been resistant to 
nalidixic acid and ciprofloxacin (Dargatz et al., 2000; Beach et al., 2002; Dargatz et al., 2003; 
Fluckey et al., 2007; Alam et al., 2009).  The 2011 National Antimicrobial Resistance 
Monitoring System (NARMS) Meat Retail Report showed a similar trend in the number of 
quinolone resistant isolates recovered from ground beef (FDA, 2014).  Salmonella isolates 
recovered from retail ground beef (n = 1,320) collected from eleven U.S. states were all 
susceptible to both ciprofloxacin and nalidixic acid (FDA, 2014).  These results, and those first 
reported here, are important as Salmonella is a leading cause of foodborne illnesses in the United 
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States (CDC, 2012), and quinolones are considered a critically important class of antimicrobials 
for human health (FDA, 2003). 
 Follow-up serotype testing of the one resistant isolate recovered during our study 
revealed that it was Salmonella serotype Cerro. This serotype has been isolated from both US 
beef and dairy cattle and has been associated with human salmonellosis (Kunze et al., 2008; 
Cummings et al., 2010; Hoelzer et al., 2011).  However, the incidence of human salmonellosis 
cases due to resistant Salmonella Cerro has been extremely low, with the majority of the 
resistance being attributed to non-fluoroquinolone drugs (Kunze et al., 2008; Cummings et al., 
2010; Hoelzer et al., 2011).    
  Cross-sectional, pen-level studies designed to evaluate the prevalence of foodborne 
pathogens in pre-harvest feedlot cattle and their antimicrobial susceptibilities may be useful in 
assessing the potential human health risks.  However, data collected from this type of study have 
limited value for causal inferences because the sequence of events that lead to the observed 
outcome cannot be determined (Mann, 2003).  Lack of history of fluoroquinolone use prior to 
cattle’s entry into the feedlot and lack of knowledge regarding the temporal dynamics of 
Salmonella within cattle and within their environment are limitations of the current study.  
However, this study provides estimates of the pre-harvest fecal prevalence of Salmonella and the 
susceptibility of recovered isolates to two quinolones that are used for human therapy.  
Importantly, the results also demonstrate no evidence of an association between the number of 
previous fluoroquinolone treatments administered to cattle and the within pen-level fecal 
prevalence of Salmonella prior to harvest.           
 This cross-sectional study indicates that Salmonella prevalence in pre-harvest feedlot 
cattle is highly variable among feedlots and across pens within feedlots.  The prevalence of 
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quinolone-resistant Salmonella in this study population was extremely low, with all but one of 
the 380 recovered isolates being susceptible to both nalidixic acid and ciprofloxacin.  Given that 
we purposely selected feedlots that used a fluoroquinolone for treating cattle with BRD, this 
study population could have been considered potentially higher risk for resistance; yet the level 
of Salmonella resistance was negligible.  While Salmonella as a foodborne pathogen, as well as 
the use of antimicrobial drugs in livestock both remain critically important issues, this study 
found no evidence of an association between fluoroquinolone treatments administered to feedlot 
cattle and the within pen-level fecal prevalence of Salmonella prior to harvest.  
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Table 2-1: Summary of Demographic Characteristics for Pens of Cattle within Feedlots that were tested for Salmonella    
 
Feedlot 
Number of Pens 
(steers/heifers) 
Mean # of 
Cattle per 
Pen 
Mean # of Days 
on Feed at 
Sampling 
(range) 
Mean Cattle 
Body Weight, 
in kg, 
at Feedlot 
Arrival (range) 
Number of Pens that 
Received an Antimicrobial 
for Metaphylaxisa (product) 
Mean # of 
Fluoroquinoloneb 
Treatments per 100 
Cattle 
(range) 
A 10 
(9/1) 
158.4 150.0 
(139-162) 
317.0 
(273-362) 
2 
(Tilmicosin) 
5.3 (1-22) 
B 10 
(10/0) 
125.2 183.0 
(148-209) 
290.5 
(248-318) 
10 
(Tulathromycin) 
19.2 (4-32) 
C 10 
(4/6) 
96.3 178.2 
(137-240) 
288.9 
(215-344) 
2 
(Streptomycin Sulfate) 
10.1 (0-36) 
D 10 
(3/7) 
198.6 163.9 
(102-203) 
300.0 
(259-352) 
8 
(Tulathromycin) 
22.8 (5-66) 
E 10 
(2/7; one mixed) 
117.3 155.5 
(118-210) 
288.7 
(226-382) 
10 
(Tulathromycin) 
7.7 (1-15) 
 
aUsed for control of bovine respiratory disease in high risk cattle 
bCattle treated for respiratory disease were treated with the same fluoroquinolone.  
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Table 2-2: Sample-Level Fecal Prevalence and Presumptive Serogroups of Salmonella for Five U.S. Commercial Feedlots. 
 
Feedlot Prevalence 95% CIa Serogroup C1b Serogroup C2b Serogroup Db Serogroup Eb 
A 0.5% (1/200) 0.1-3.6% 0.0% (0/1) 0.0% (0/1) 0.0% (0/1) 100.0% (1/1) 
B 17.5% (35/200) 12.7-23.6% 33.3% (11/33) 3.0% (1/33) 0.0% (0/33) 63.6% (21/33) 
C 37.0% (74/200) 30.4-44.1% 28.2% (20/71) 28.2% (20/71) 2.8% (2/71) 40.8% (29/71) 
D 58.5% (117/200) 51.4-65.3% 52.4% (55/105) 3.8% (4/105) 0.0% (0/105) 43.8% (46/105) 
E 
 
 
76.5% (153/200) 70.0-82.0% 60.8% (93/153) 16.3% (25/153) 0.0% (0/153) 22.9% (35/153) 
Total 38.0% (380/1000)  49.3% (179/363) 13.8% 
(50/363) 
0.6% 
(2/363) 
36.4% 
(132/363) 
aCI = Confidence Interval 
b Out of the 380 isolates tested, 17 isolates did not test positive for any of the serogroups (B, C1, C2, D1, D2, and E) evaluated.   
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Table 2-3: Results from Univariable Mixed Modelsa of Associations between Pen-Level 
Risk Factors and Within-Pen Prevalence of Salmonella 
Variable, units 
Number 
of  
Pens 
Mean 
Prevalence 
(%) 
95% 
Confidence 
Intervals (%) P-value 
Number of fluoroquinolone 
treatments for bovine 
respiratory disease per 100 
cattle (in quartiles) 
     
0.52 
0-2 13 20.3 3.5-76.8 
 3-8 12 26.7 4.6-87.0 
 9-23 13 26.9 4.6-87.3 
 24-66 12 31.4 5.6-91.6 
 Sexb    0.35 
Steer 28 24.3 4.1-84.2 
 Heifer 21 29.3 5.1-90.0 
 Metaphylaxis use    0.33 
No 18 21.9 3.9-78.8 
 Yes 32 28.9 5.0-89.5 
 Body weight at arrival, kg 
(in quartiles)  
  
0.02 
215-265 12 31.2c 5.0-93.5 
 266-298 13 15.7d 2.4-70.5 
 299-319 11 25.7cd 4.1-88.0 
 320-382 14 30.2c 4.8-92.7 
 Days on feed  
(in quartiles)  
  
0.94 
102-145 11 25.3 4.1-86.7 
 146-161 14 25.3 4.2-86.0 
 162-192 12 25.5 4.1-87.0 
 193-240 13 28.4 4.7-90.2 
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aModels included a random effect to account for lack of independence among pens within 
feedlots 
bOne pen was a mixed of heifers and steers, and was removed from this analysis 
c,dRow values with different superscripts differ (p < 0.05).  
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Chapter 3 - Campylobacter prevalence and quinolone susceptibility 
in feces of pre-harvest feedlot cattle pens exposed to various levels 
of enrofloxacin for the treatment of bovine respiratory disease 
 Abstract 
Campylobacter spp., which are commensal to cattle and can be pathogenic to humans, often 
harbor antimicrobial resistance genes. Data on quinolone resistance in relation to antimicrobial 
use in beef cattle are scarce. Therefore, the objective of our study was to evaluate Campylobacter 
prevalence and susceptibility to nalidixic acid and ciprofloxacin in pens of cattle at five different 
feedlots that were administered a fluoroquinolone as the primary treatment for bovine respiratory 
disease (BRD). Twenty, fresh, pen-floor samples were collected from each of 10 pens from each 
feedlot, 1-2 weeks prior to cattle being harvested. Fecal samples were cultured for 
Campylobacter using enrichment and selective isolation methods and confirmed by PCR. 
Minimum inhibitory concentrations (MICs) of ciprofloxacin and nalidixic acid were determined 
using a micro-broth dilution method and human quinolone breakpoints. The number of 
fluoroquinolone treatment used within each pen were recorded and summarized.  Data analyses 
were performed using generalized linear mixed-models (prevalence) and survival analysis 
(MICs).  Overall sample prevalence of Campylobacter was 27.2% (272/1000) and was 
significantly different among feedlots (P < 0.01). Campylobacter coli was the most prevalent 
species (55.1%; 150/272), followed by Campylobacter hyointestinalis (42.6%; 116/272). 
Prevalence was not significantly associated with the number of fluoroquinolone treatments, sex, 
body weight or metaphylaxis use, but was associated with the number of days the cattle were in 
the feedlot (P = 0.03). Susceptibility testing revealed that several isolates (68.4%; 175/256) were 
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above the breakpoint for nalidixic acid (≥ 64 µg/mL) and above the breakpoint ( ≥ 4 µg/mL) for 
ciprofloxacin (65.6%; 168/256). Distributions of MICs for individual feedlots, and by 
Campylobacter species, were significantly different for isolates tested against nalidixic acid (P ≤ 
0.01).  A similar trend was noted for isolates tested against ciprofloxacin (P ≤ 0.05). The number 
of fluoroquinolone treatments, sex, body weight, days on feed and metaphylaxis use were not 
significantly associated with the differences in MIC distributions among feedlots and within 
pens.  In this study we found no evidence that the number of fluoroquinolone treatments 
administered to cattle affects fecal prevalence of Campylobacter or the sample-level prevalence 
of resistance to nalidixic acid or ciprofloxacin. 
 
 
 Introduction 
 In 2013, the Center for Disease Control and Prevention (CDC) reported that drug-
resistant Campylobacter is considered a serious threat to the United States and requires 
immediate action to ensure the problem does not continue to grow (CDC, 2013).  The CDC 
estimates that more than 1 million Campylobacter infections are reported each year, leading to 
13,000 hospitalizations and 120 deaths. Of the cases reported, 310,000 are found to be drug-
resistant (CDC, 2014).  Campylobacter causes bloody diarrhea, fever and abdominal cramps in 
humans.  If the organism is resistant to antimicrobial therapy, symptoms typically last longer and 
are more severe (CDC, 2014).  
 Cattle and poultry are considered reservoirs of Campylobacter, which is shed in their 
feces (Besser et al., 2005; Humphrey et al., 2007). Human illness is frequently associated with 
the consumption of undercooked meat, unpasteurized milk and contaminated water (CDC, 2014). 
Human infection with a Campylobacter species is often treated with a fluoroquinolone (Allos, 
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2001). Bovine respiratory disease, a bacterial pneumonia that causes major economic losses in 
the U.S. feedlot industry, can also be treated with a fluoroquinolone (Bateman et al., 1990).  
Because antimicrobial drug use contributes to the emergence of drug resistant organisms, the 
U.S. Food and Drug Administration (FDA) recommends that drugs used in both human and 
animal medicine be used judiciously (FDA, 2012).  
 The judicious use of an antimicrobial in food-producing cattle is defined as: 1) limiting 
medically important antimicrobials to uses considered necessary for assuring the health and well-
being of animals and 2) only using these drugs under the consultation and supervision of a 
veterinarian (FDA, 2012).  Evaluating the judicious use of antimicrobials in the feedlot industry 
helps to assure that the public health is protected and animal health needs are being met. 
Therefore, the objective of this study was to assess the prevalence of Campylobacter and its 
antimicrobial susceptibilities to human quinolones, isolated from pens of pre-harvest, 
commercial feedlot cattle that were treated with a fluoroquinolone for bovine respiratory disease 
(BRD). These data enable estimates of Campylobacter prevalence and antimicrobial 
susceptibility in pens of cattle administered various amounts of antimicrobial therapy, and an 
assessment of whether gender, body weight, the number of days cattle were at the feedlot (“days 
on feed”) and metaphylaxis use (whole pen use of an antimicrobial) are significantly associated 
with these prevalence estimates.    
 
 Materials and Methods 
  Study Population 
  Five commercial feedlots in Texas and western Kansas were selected for this study. 
Feedlots were selected as a convenience sample based on their use of a fluoroquinolone 
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(Baytril® 100) as first-line therapy for the treatment of BRD and proximity to Kansas State 
University Pre-Harvest Food Safety Lab. Ten study pens with various levels of BRD morbidity 
rates were selected by feedlot personnel based on their projected harvest dates.  Data regarding 
antimicrobials administered to cattle within study pens while at the feedlot were collected and 
summarized. 
 Between May and July of 2012, 20 freshly voided fecal samples were collected from the 
pen floor of each study pen (N=10 pens/feedlot), which were approximately 1 to 2 weeks prior to 
harvest, within each feedlot (N=200 samples/feedlot). Cattle feces were collected using new 
plastic spoons, placed in individual Whirlpak bags (Nasco, Inc., Fort Atkinson, WI) and 
transported on ice to the Kansas State University pre-Harvest food safety laboratory for 
processing and analysis. 
  Isolation of Campylobacter 
 Campylobacter was isolated from each fecal sample collected using a published isolation 
method (Burrough et al., 2013).  Briefly, each fecal sample was diluted 1:10 (1 g feces to 9 ml 
broth) in Mueller-Hinton broth (Becton Dickinson Co., Sparks, MD) containing selective 
(polymyxin B, rifampicin, trimethoprim, and cycloheximide; Oxoid, Cambridge, UK) and 
growth supplements (SS; sodium pyruvate, sodium metabisulfite and ferrous sulfate; Oxoid, 
Cambridge, UK) and incubated under microaerophilic conditions (5% oxygen, 10% carbon 
dioxide and 85% nitrogen) at 42°C for 48 h. Using a sterile, disposable cotton swab, the broth 
culture was streaked for isolation onto Mueller Hinton agar (Becton Dickinson Co., Sparks, MD) 
with selective and growth supplements (MH+SS) and incubated under microaerophilic 
conditions at 42°C for 48 h. Plates were observed for Campylobacter growth and three, well-
isolated colonies per sample were streaked for isolation onto MH agar. Plates were incubated at 
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42°C for 24-30 h under microaerophilic conditions. After incubation, pure culture from each agar 
plate was transferred to separate cryovials containing MH broth and 30% glycerol (Fisher, Fair 
Lawn, NJ). Samples were stored at -80°C until genus confirmation and species identification 
were performed.  
  Campylobacter Confirmation and Speciation 
 Suspect Campylobacter colonies were removed from the freezer and streaked for 
isolation on MH+SS agar plates. The plates were incubated at 42°C for 48 h under 
microaerophilic conditions. Approximately 2 to 3 colonies were transferred to single cell lysis 
buffer (1 ml Tris-EDTA (1x TE) + 10 µl proteinase K (5 mg/ml)) for DNA extraction (Olah, et 
al., 2006).  Multiplex polymerase chain reaction (PCR) was used to identify Campylobacter 
genus and six species: jejuni, coli, lari, fetus, upsaliensis and hyointestinalis subsp. 
hyointestinalis (Yamazaki-Matsune et al., 2007). Campylobacter coli NCTC 36572, 
Campylobacter jejuni ATCC 33560, Campylobacter hyointestinalis subsp. hyointestinalis ATCC 
35217, Campylobacter lari ATCC 35222, Campylobacter fetus subsp. fetus ATCC 27374, and 
Campylobacter upsaliensis ATCC 49815 were used as positive controls.    
  Susceptibility Testing 
 A micro-broth dilution method, described by the Clinical and Laboratory Standards 
Institute (CLSI, 2008), was used to determine the minimum inhibitory concentrations (MICs) of 
nalidixic acid and ciprofloxacin for Campylobacter isolates tested. One isolate per fecal sample 
collected was tested.    
 Stock solutions of ciprofloxacin and nalidixic acid (Sigma-Aldrich, St. Louis, MO) were 
prepared in sterile, distilled water at a concentration of 1 mg/mL based on the potency of the 
antibiotic. Nalidixic acid was tested at concentrations of 100, 50, 25, 12.5, 6.25, 3.125, 1.56, 
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0.78, 0.39 and 0.195 µg/mL and ciprofloxacin was tested at concentrations of 25, 12.5, 6.25, 
3.152, 1.56, 0.78, 0.39, 0.195, 0.098 and 0.049 µg/mL.  
 Inoculum was prepared by streaking pure, Campylobacter culture for each sample onto 
MH+SS agar and incubating at 42°C for 48 hours. A single isolate from each plate was sub-
cultured onto MH agar (without supplements) and incubated for 24-30 hours at 42°C. Pure 
culture was then transferred to 3mL MH II broth using a sterile, disposable swab.  A 
spectrophotometer (OD 600) and MH II broth was used to adjust the innoculum, so that it was 
equivalent to 0.5 McFarland standard.  A 1:100 dilution of the inoculum was then prepared using 
MH II broth and 2.5% lysed horse blood.  
 The antimicrobial susceptibilities were performed in 96-well microtiter plates (Becton 
and Dickinson Co., Sparks, MD) and quality control organism, Campylobacter jejuni ATCC# 
33560 was used to ensure the validity of the test.   Plates were sealed with perforated plate 
covers and incubated at 37°C under microaerophilic conditions for 48 h.  Results were recorded 
as either growth or no growth (color change) within each well.  This process was performed 
separately for each antibiotic (ciprofloxacin and nalidixic acid) and each Campylobacter isolate 
was tested in quadruplicate. The minimum inhibitory concentration (MIC) was determined by 
the lowest concentration of antimicrobial agent that completely inhibited the growth of the 
organism (CLSI, 2008). Campylobacter isolates were considered resistant to nalidixic acid and 
ciprofloxacin if the MIC was ≥ 64 µg/mL and ≥ 4 µg/mL, respectively (CLSI, 2010 ; NARMS, 
2011).       
  Statistical Analysis 
 Campylobacter within-pen prevalence and associations with antibiotic use and 
demographic characteristics of the study pens were evaluated using generalized linear mixed 
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models.  These models were fitted using binomial distribution, maximum likelihood estimation, 
complimentary-log-log link, Kenward-Roger degrees of freedom and Newton-Raphson and 
Ridging optimization procedures (Proc GLIMMIX SAS 9.3, SAS Institute, Inc., Cary, NC, 
USA).   Feedlot was included as a random intercept to account for the lack of independence of 
observations (samples) made within pens within each feedlot.  
 Campylobacter prevalence was modeled as a binomial outcome by including the number 
of Campylobacter test-positive samples in a pen (“events”) divided by the number of samples 
collected per pen (“trials”). The number of BRD fluoroquinolone treatments administered, body 
weight at arrival, days on feed, sex (steers/heifers) and antimicrobial metaphylaxis use in the pen 
(use/no use) were included as independent variables.  The variable pertaining to the number of 
fluoroquinolone treatments was categorized by the number of treatments per 100 cattle due to the 
variability in pen size. Continuous variables that did not meet the linearity assumption (i.e., 
number of fluoroquinolone treatments per 100 cattle, body weight and days on feed) were 
categorized in quartiles.  
 Correlation analysis was performed prior to building the multivariable model to identify 
highly correlated variables (≥ |0.80|).  Our variable of interest (number of fluoroquinolone 
treatments per 100 cattle) was forced in our multivariable model regardless of its significance.  
Testing for a priori confounders and two-way interactions was performed by keeping those 
variables in the model that had a > 20% change in the magnitude of the association (confounder) 
and when the interaction was statistically significant (P < 0.05). Following forward selection, if a 
variable was found to be non-significant (P > 0.05), it was removed from the model and 
prevalence estimates (means and 95% confidence intervals) for the univariable model were 
reported for that variable.  Residual diagnostics were used to assess model assumptions and 
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overall model fit. Best linearized unbiased predictors (BLUPs) were used to evaluate residuals at 
the feedlot level, and Pearson and Deviance residuals were used to evaluate residuals at the pen-
level.  
 Because antimicrobial susceptibility testing was performed in quadruplicate for all 
Campylobacter isolates, the mode MIC value was reported for each isolate. When two different 
MIC values for one isolate were recorded, the MIC value with the highest concentration was 
reported.  If four different MIC values were recorded, the isolate was re-tested and either the 
mode or the highest MIC value was reported. The overall proportion of Campylobacter isolates 
at each MIC for both nalidixic acid and ciprofloxacin were summarized using descriptive 
statistics.  
 In lieu of dichotomizing the susceptibility outcomes in terms of susceptible or resistant 
isolates, semi-parametric survival analysis was used to analyze the pen-level distribution of the 
MIC values for isolates recovered from each of the five feedlots (STATA 10, StataCorp LP, 
College Station, TX). Cox proportional hazard shared frailty regression model was fitted to 
evaluate the distribution of the MICs for each drug tested (nalidixic acid and ciprofloxacin) and 
their association with where the isolates were recovered from (Feedlot), species (C. coli, C. 
hyointestinalis, or “other” species), number of fluoroquinolone treatments for BRD per 100 
cattle, gender, metaphylaxis use, arrival body weight and days on feed. The hazard was defined 
as isolates that failed to grow at a specific breakpoint (MIC value).  Frailty was used to account 
for clustering within feedlot. Hazard ratios were documented for all variables tested (univariable 
model) and those variables found significant (P < 0.05) were included in the (multivariable) 
model, along with our exposure variable of interest (# of fluoroquinolone treatments per 100 
head of cattle). The proportional hazard assumption was assessed using the log cumulative 
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hazard plot and Schoenfeld residuals. Martingale residuals were used to evaluate model fit 
(Goodness of Fit test), as well as to evaluate outlying observations at the pen-level. 
 
 Results 
  Cattle Demographics 
 Demographic characteristics of cattle within study pens across the five feedlots were 
previously described in Smith et al., 2016. Briefly, the majority (56%; 28/50) of the cattle in 
study pens were steers with one pen including both steers and heifers.  The pen-level mean body 
weight of cattle on feedlot arrival ranged from 289 kg to 317 kg across the five feedlots and the 
mean number of days on feed ranged from 96 to 199 days. All feedlots had at least one pen that 
received a metaphylaxis antimicrobial for the control of BRD and the mean number of 
fluoroquinolone treatments per 100 cattle ranged from 5 to 23 treatments, with no 
fluoroquinolone treatments administered to two pens within one feedlot (Feedlot C). 
  Campylobacter Prevalence  
 Overall prevalence of Campylobacter isolated from cattle feces across all five feedlots 
was 27.2% (272/1000). Sample-level prevalence of Campylobacter varied significantly (P < 
0.01) across feedlots ranging from 14.5% (29/200) to 40.0% (80/200) (Figure 1). Within-pen 
prevalence ranged from 0.0% (0/20) to 60.0% (12/20).  Campylobacter coli was the most 
prevalent species (55.1%; 150/272) isolated, followed by C. hyointestinalis (42.6%; 116/272). 
Species was not identified for six isolates (2.2%; 6/272), because we only tested for six species 
(jejuni , coli , lari, fetus, upsaliensis and hyointestinalis). Campylobacter jejuni was not isolated 
from any of the cattle feces collected in this study.     
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 Results from the evaluation of the potential associations between the number of 
fluoroquinolone treatments per 100 cattle, sex, metaphylaxis use, arrival body weight, the 
number of days on feed, and within-pen prevalence of Campylobacter are illustrated in Table 1. 
The number of days cattle were on feed at the time of sample collection was significantly 
associated with the within-pen prevalence of Campylobacter (Table 1). Cattle that were fed for 
102 to 145 days had significantly lower prevalence of Campylobacter than those that were fed 
for 146 to 161 days (P = 0.03) or 162 to 192 days (P = 0.02).     
 The number of fluoroquinolone treatments per 100 cattle was not statistically significant 
(P = 0.63). However it was forced into the multivariable model with the significant variable, 
“days on feed,” because it was considered our main variable of interest.  After accounting for the 
number of fluoroquinolone treatments, cattle that were fed for 102 to 145 days had significantly 
lower prevalence of Campylobacter (19.5%; 95% CI = 12.2 to 30.0) than cattle that were fed for 
162 to 192 days (33.2%; 95% CI = 22.9 to 45.5; P = 0.03).  No other statistically significant 
differences were found among the other (days on feed) quartiles.   
 When testing whether the number of fluoroquinolone treatments per 100 cattle was 
associated with any of the Campylobacter species, results indicated that the number of 
fluoroquinolone treatments per pen was not associated with the prevalence of C. coli (P = 0.39) 
or C. hyointestinalis (P = 0.85).  Isolates that did not have species identified were not analyzed 
due to the small sample size (6 isolates). 
  Campylobacter Susceptibility Results 
 There were 256 viable Campylobacter isolates available for susceptibility (MIC) testing. 
Of the isolates tested, 31.6% (81/256) were susceptible to nalidixic acid and 34.4% (88/256) 
were susceptible to ciprofloxacin.  Several isolates (68.4%; 175/256) were above the breakpoint 
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for nalidixic acid ( ≥ 64 µg/mL) and above the breakpoint ( ≥ 4 µg/mL) for ciprofloxacin 
(65.6%; 168/256).  
 The MIC results for C. coli isolates from each feedlot are illustrated in Table 2. MICs 
ranged from 3.13 µg/mL to > 100µg/mL for nalidixic acid and 0.05 µg/mL to 25.00 µg/mL for 
ciprofloxacin across all feedlots, with most of the C. coli isolates having a MIC of 100.00 µg/mL 
for nalidixic acid and a MIC of 6.25 µg/mL for ciprofloxacin.  The MIC results for C. 
hyointestinalis isolates from each feedlot are illustrated in Table 3. MICs for these isolates 
ranged from 25.00 to > 100.00 µg/mL for nalidixic acid and 0.20 µg/mL to 25.00 µg/mL for 
ciprofloxacin, with most of the isolates having a MIC > 100.00 µg/mL for nalidixic acid and a 
MIC of 25.00 µg/mL for ciprofloxacin.    
 Univariable survival analysis revealed that the number of fluoroquinolone treatments 
within each pen, sex, arrival body weight, and days on feed categories were not significantly 
associated with the MIC results for nalidixic acid and ciprofloxacin for the Campylobacter 
isolated (Tables 4 and 5). However, the feedlot from where the isolates were collected (P ≤ 
0.01), species (P ≤ 0.01) and whether or not a metaphylaxis antimicrobial was used (P ≤ 0.05) 
were significantly associated with MIC results for naladixic acid and ciprofloxacin (univariable 
models; Table 4).  In the multivariable model, after forcing the variable pertaining to the number 
of fluoroquinolone treatments per 100 cattle into the model, only feedlot (P ≤ 0.01) and isolated 
species (P ≤ 0.01), remained significantly associated with the MIC distribution for the 
Campylobacter isolated (main effects model).   
 The distribution of the MICs for Campylobacter isolates tested against ciprofloxacin was 
similar to nalidixic acid (Table 5). The MIC distributions were significantly different among 
feedlots (P ≤ 0.01) and were dependent upon species (P ≤ 0.01). No other variables were found 
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to be associated with the difference in the MIC distribution when each variable was tested 
separately (univariable model; Table 5). When our variable of interest (# of fluoroquinolone 
treatments per 100 head of cattle) was forced into the model, the MIC distributions were still 
significantly different among feedlots (P = 0.05) and species (P = 0.02).  No other variable tested 
was significantly associated with the outcome (Table 5).             
 Discussion  
 This study provides Campylobacter prevalence estimates and quinolone susceptibility 
data for pre-harvest feedlot cattle administered a fluoroquinolone for the treatment of BRD.  It 
also provides evidence that the number of previous fluoroquinolone treatments administered to 
cattle during the feedlot production phase does not significantly impact the prevalence or the 
MIC distributions for Campylobacter.    
 Cumulative sample-level fecal prevalence of Campylobacter for this study was fairly low 
with only 272 of the 1000 (27.2%) fecal samples collected across all five feedlots positive for 
this organism. Though published Campylobacter prevalence data for beef cattle are relatively 
scarce, fecal prevalence estimates from previous studies range from 20-70% (Beach et al., 2002; 
Bae et al., 2005; Krueger et al., 2008; Abley et al., 2012). Campylobacter prevalence was highly 
variable across all feedlots and within pens of cattle, with some pens having no samples test 
positive for the organism of interest.  Prevalence of Campylobacter in cattle are believed to be 
affected by numerous factors such as season, stress, farm management factors and diet (Wesley 
et al., 2000; Sproston et al., 2011).  Though all samples were collected within the same season 
(May thru July; sampled in consecutive order “Feedlot A-E”) and within a similar geographic 
region (Western Kansas and Northwestern Texas), factors such as feedlot management practices 
may have accounted for the variability in prevalence (Krueger et al., 2008; Hannon et al., 2009).   
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 Campylobacter coli was the most prevalent species isolated for this study, followed by 
Campylobacter hyointestinalis. According to the literature, C. coli and C. hyointestinalis, though 
more commonly seen in poultry and swine feces, have been previously isolated from cattle 
(Inglis et al., 2003; Laatu et al., 2005; Sanad et al., 2011; Sproston et al., 2011; Mattheus et al., 
2012; Quintana-Hayashi et al., 2012; Gaudreau et al., 2014). Campylobacter coli has been found 
to be pathogenic to humans, though C. jejuni is the species more commonly associated with 
foodborne illness (Allos, 2001; FDA, 2012; Taylor et al., 2013). Approximately 90% of the 
human Campylobacteriosis cases each year are caused by C. jejuni, while only 10% are caused 
by C. coli (FDA, 2016). Campylobacter jejuni is typically one of the most prevalent species 
isolated from both dairy and beef cattle (Wesley et al., 2000; Besser et al.,2005; Sproston et al., 
2011). However, C. jejuni was not isolated from any of the fecal samples collected during this 
study.   
 The number of fluoroquinolone treatments per 100 cattle, metaphylaxis use, body weight 
or gender were not significantly associated with the within pen-prevalence of Campylobacter. 
However, Campylobacter pen-prevalence significantly differed with the number of days cattle 
were in the feedlot. Specifically, pens of cattle fed for 146-192 days had significantly more 
Campylobacter than cattle fed 102-145 days after arrival at the feedlot. This was similar to what 
Besser and others found in 2005 where Campylobacter prevalence increased significantly 
throughout the feeding period. The opposite was reported in 2011 where Campylobacter 
prevalence was the highest at feedlot entry (32.1%) and reduced to 11.8% at final sampling 
(Sproston et al., 2011). With various outcomes being reported, we conclude that the number of 
days cattle are in the feedlot may not be a consistent predictor of Campylobacter prevalence at 
harvest. In the current study, other factors such as the environment and feedlot management 
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practices may have contributed to the increase in Campylobacter prevalence 140+ days after 
arrival. Numerous Campylobacter isolates recovered from fecal samples collected for this study 
were above the breakpoint for both nalidixic acid (175/256 ≥ 64 µg/mL) and ciprofloxacin 
(168/256; ≥ 4 µg/mL). Since a large portion of the isolates available for susceptibility testing 
were C. coli, (55.1%; 141/256), these results were expected. Previous studies in cattle have 
shown that C. coli, under fluoroquinolone selection pressure, tend to be resistant to quinolones 
(Englen et al., 2005; Inglis et al., 2006; Sanad et al., 2011; Gaudreau et al., 2014). 
Campylobacter coli, as well as other Campylobacter species, are able to resist quinolone 
antimicrobial therapy by a single point mutation in the quinolone resistance-determining region 
(QRDR) of DNA gyrase A (Alfredson et al., 2007; Luangtongkum et al., 2009). When the 
mutation occurs, the quinolone is unable to bind allowing for decreased susceptibility to the drug 
(Alfredson et al., 2007; Luangtongkum et al., 2009).  
 The distributions of MICs for nalidixic acid and ciprofloxacin were significantly different 
among the five feedlots. Similar to prevalence, feedlot management practices and environmental 
factors may have contributed to the variability in the susceptibility results. It is unclear how 
drug-resistant Campylobacter isolates survive in the environment and persist without 
antimicrobial selection pressure. However, enhanced fitness and transmission of these resistant 
isolates in the environment may play an important role in the variability in the prevalence of 
these resistant isolates at different feedlots (Zhang et al., 2003; Luo et al., 2005; Zhang et al., 
2006).    
 Distributions of MICs were significantly different (P < 0.05) between Campylobacter 
species for both drugs tested. Numerical differences in the prevalence of C. coli and C. 
hyointestinalis were observed among feedlots, which may explain the variation in the MIC 
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results (Tables 2 and 3). Also, previous studies have shown that C. coli tend to have higher 
resistance prevalence to quinolones when compared to other species of Campylobacter (Moore et 
al., 2006; Smith and Fratamico, 2010; Gaudreau et al., 2014). The number of fluoroquinolone 
treatments per 100 cattle, sex, metaphylaxis use, body weight and days on feed were not 
significantly associated with MIC distributions.    
       Data from this cross-sectional study can be used to help evaluate the use of 
fluoroquinolone therapy in feeder cattle and the potential association with the prevalence of 
pathogenic bacteria and their susceptibility to human quinolones.   There are, however, 
limitations to this study design (Mann, 2003).  Without the history of fluoroquinolone use prior 
to cattle arriving at the feedlot, and without more comprehensive knowledge of the epidemiology 
of Campylobacter both within cattle and within their environment, causal inferences are limited.  
We can conclude, however, that administering a fluoroquinolone to beef cattle for the treatment 
of BRD was not significantly associated with the prevalence of Campylobacter, and though MIC 
values for Campylobacter isolates were generally high, there was no evidence that the 
distribution of the MICs was associated with fluoroquinolone treatment administered within 
study pens.      
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Figure 3-1: Cumulative Sample-Level Fecal Prevalence of Campylobacter in Five  
U.S. Commercial Feedlots (n = 200 total samples/feedlot; 20 from each of 10 pens).  
Error Bars Represent 95% Exact Confidence Intervals For Proportions. 
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Table 3-1: Results from Univariable Mixed Modelsa of Associations between Pen-Level 
Risk Factors and Within-Pen Prevalence of Campylobacter 
Variable, units 
Number 
of 
Pens 
Mean 
Prevalence 
(%) 
95% 
Confidence 
Intervals 
(%) P-value 
Number of 
fluoroquinolone 
treatments for BRD per 
100 cattle (in quartiles) 
     
0.63 
0-2 13 29.8 19.9-42.0 
 3-8 12 24.3 15.7-35.6 
 9-23 13 28.3 19.0-40.1 
 24-66 12 23.0 14.4-35.0 
 Sexb    0.87 
Steer 28 26.0 17.4-36.9 
 Heifer 21 26.7 17.6-38.3 
 Metaphylaxis use    0.22 
No 18 30.5 21.5-41.2 
 Yes 32 24.4 17.7-32.7 
 Body weight at arrival, kg 
(in quartiles)  
  
0.34 
215-265 12 26.4 16.5-39.4 
 266-298 13 30.6 19.9-43.8 
 299-319 11 27.1 16.8-40.7 
 320-382 14 21.9 13.6-33.4 
 Days on feed  
(in quartiles), days  
  
0.04 
102-145 11 20.1c 12.5-30.6 
 146-161 14 31.2d 21.2-43.3 
 162-192 12 31.8d 21.7-43.9 
 193-240 13 21.7cd 13.8-32.4 
 aModels included a random effect to account for lack of independence among pens within 
feedlots 
bOne pen was a mixed of heifers and steers, and was removed from this analysis 
c,dColumn values with different superscripts differ (P < 0.05).  
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Table 3-2: Minimum Inhibitory Concentration (MIC) results for Nalidixic acid and Ciprofloxacin for Campylobacter coli 
Isolates Recovered from Cattle Feces from the Five Feedlots Sampled 
 
 Nalidixic acid Ciprofloxacin 
Feedlot % C. coli 
Mode MIC 
(µg/mL) 
MIC Range 
(µg/mL) % aResistant 
Mode MIC 
(µg/mL) 
MIC Range 
(µg/mL) % bResistant 
A 79.3 (65/82) 100 6.25 to > 100 60.0 (39/65) 6.25 0.195 to 25 73.8 (48/65) 
B 88.5 (23/26) 50 3.125 to > 100 26.1 (6/23) 6.25 0.049 to 12.5 78.3 (18/23) 
C 7.2 (5/69) 100 25 to > 100 60.0 (3/5) 12.5 6.25 to 12.5 80.0 (4/5) 
D 78.6 (33/42) 12.5 6.25 to > 100 24.2 (8/33) 0.195 0.195 to 25 30.3 (10/33) 
E 40.5 (15/37) 100 25 to 100 46.7 (7/15) 6.25 0.195 to 12.5 86.7 (13/15) 
aNalidixic acid resistance breakpoint is ≥ 64 µg/mL. 
bCiprofloxacin resistance breakpoint is ≥ 4 µg/mL. 
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Table 3-3: Minimum Inhibitory Concentration (MIC) results for Nalidixic acid and Ciprofloxacin for Campylobacter 
hyointestinalis Isolates Recovered from Cattle Feces from the Five Feedlots Sampled 
 
 Nalidixic acid Ciprofloxacin 
Feedlot 
% C. 
hyointestinalis 
Mode MIC 
(µg/mL) 
MIC Range 
(µg/mL) % aResistant 
Mode MIC 
(µg/mL) 
MIC Range 
(µg/mL) % bResistant 
A 19.5 (16/82) 100 25 to > 100 87.5 (14/16) 25 0.195 to 25 68.8 (11/16) 
B 7.69 (2/26) > 100 N/A 100.0 (2/2) 12.5 N/A 100.0 (2/2) 
C 89.9 (62/69) > 100 N/A 100.0 (62/62) 25 0.195 to 50 66.1 (41/62) 
D 21.4 (9/42) > 100 50 to > 100 88.9 (8/9) 12.5 0.195 to 25 77.8 (7/9) 
E 54.1 (20/37) 100 100 to > 100 100.0 (20/20) 0.195 0.195 to 25 45.0 (9/20) 
aNalidixic acid resistance breakpoint is ≥ 64 µg/mL. 
bCiprofloxacin resistance breakpoint is ≥ 4 µg/mL. 
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Table 3-4: Results from Univariable and Multivariable Survival Analysis Modelsa Testing Associations between Pen-level Risk 
Factors and Within-Pen Distributions of Minimum Inhibitory Concentrations (MICs) for Nalidixic acid for Campylobacter 
isolated from Five U.S. Commercial Feedlots 
 
 Univariable Model Multivariable Model 
Variable, units 
Number 
of  
Pens Hazard Ratio 
95% 
Confidence 
Intervals 
(%) p-value 
Hazard 
Ratio 
95% 
Confidence 
Intervals 
(%) p-value 
Feedlot    ≤ 0.01   ≤ 0.01 
A 10 Referencec .  Referencec .  
B 10 1.45c 0.85-2.48  1.76cd 0.92-3.36  
C 10 0.29d 0.17-0.49  0.65ce 0.36-1.16  
D 10 1.60c 1.00-2.59  2.43d 1.34-4.26  
E 10 0.78c 0.48-1.28  1.18c 0.65-2.15  
Species    
≤ 0.01   ≤ 0.01 
C. coli  Referencec .  Referencec .  
C. hyointestinalis  0.29d 0.20-0.41  0.40d 0.27-0.61  
“Other”f   0.33cd 0.10-1.04  0.41cd 0.13-1.33  
Number of 
fluoroquinolone 
treatments for BRD 
   
0.97   0.45 
71 
per 100 cattle (in 
quartiles) 
0-2 13 Reference .  Reference .  
3-8 12 1.12 0.58-2.13  0.77 0.47-1.26  
9-23 13 0.99 0.53-1.83  0.78 0.51-1.20  
24-66 12 1.13 0.57-2.22  0.60 0.31-1.17  
Sexb    0.39    
Steer 28   
 
   
Heifer 21 0.81 0.50-1.31 
 
   
Metaphylaxis use    0.05   0.90 
No 18 
 
Reference . 
 
Reference .  
Yes 32 1.58 1.00-2.49 
 
1.03 0.65-1.64  
Body weight at 
arrival, kg 
(in quartiles)  
  
0.19    
215-265 12 Reference . 
 
   
266-298 13 1.52 0.79-2.93 
 
   
299-319 11 2.19 1.08-4.46 
 
   
320-382 14 1.48 0.75-2.92 
 
   
Days on feed  
(in quartiles)  
  
0.67 
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102-145 11 Reference . 
 
   
146-161 14 1.48 0.76-2.85 
 
   
162-192 12 1.42 0.70-2.89 
 
   
193-240 13 1.21 0.57-2.57 
 
   
aUnivariable models included frailty to account for lack of independence among pens within feedlots 
bOne pen was both heifers and steers and was removed from this analysis 
c,d,eRow values with different superscripts differ (p < 0.05).  
fIsolates where species was not identified were listed as “other.” 
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Table 3-5: Results from Univariable and Multivariable Survival Analysis Modelsa Testing Associations between Pen-level Risk 
Factors and Within-Pen Distributions of Minimum Inhibitory Concentrations (MICs) for Ciprofloxacin for Campylobacter 
isolated from Five U.S. Commercial Feedlots 
 
 Univariable Model Multivariable Model 
Variable, units 
Number 
of  
Pens Hazard Ratio 
95% 
Confidence 
Intervals 
(%) p-value 
Hazard 
Ratio 
95% 
Confidence 
Intervals 
(%) p-value 
Feedlot    ≤ 0.01   0.05 
A 10 Referencec .  Referencec .  
B 10 1.12c 0.72-1.74  1.26ce 0.77-2.07  
C 10 0.62d 0.44-0.86  0.92d 0.62-1.37  
D 10 1.17c 0.81-1.71  1.64e 1.03-2.61  
E 10 1.17c 0.79-1.73  1.43ce 0.95-2.17  
Species    
≤ 0.01   0.02 
C. coli  Referencec .  Referencec .  
C. hyointestinalis  0.58d 0.43-0.77  0.63d 0.45-0.88  
“Other”f   0.52cd 0.22-1.23  0.51cd 0.21-1.24  
Number of 
fluoroquinolone 
treatments for BRD per 
     
0.60   0.15 
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100 cattle (in quartiles) 
0-2 13 Reference .  Reference .  
3-8 12 1.06 0.68-1.65  0.95 0.65-1.39  
9-23 13 0.95 0.62-1.44  0.87 0.62-1.23  
24-66 12 0.75 0.47-1.21  0.60 0.38-0.96  
Sexb    0.77    
Steer 28 Reference . 
 
   
Heifer 21 0.95 0.68-1.33 
 
   
Metaphylaxis use    0.38    
No 18 Reference . 
 
   
Yes 32 1.15 0.84-1.60 
 
   
Body weight at arrival, 
kg 
(in quartiles)  
  
0.62    
215-265 12 Reference . 
 
   
266-298 13 1.31 0.83-2.06 
 
   
299-319 11 1.03 0.63-1.70 
 
   
320-382 14 1.18 0.73-1.88 
 
   
Days on feed  
(in quartiles)  
  
0.81 
  
 
102-145 11 Reference . 
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146-161 14 1.21 0.77-1.91 
 
   
162-192 12 1.05 0.65-1.70 
 
   
193-240 13 1.19 0.72-1.96 
 
   
aUnivariable models included frailty to account for lack of independence among pens within feedlots 
bOne pen was a both heifers and steers and was removed from this analysis 
c,d, eRow values with different superscripts differ (p < 0.05).  
fIsolates where species was not identified were listed as “other.” 
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 Abstract 
The study objective was to determine effects of fluoroquinolone metaphylaxis on fecal 
prevalence of Salmonella and Campylobacter and fecal prevalence of quinolone resistant 
Salmonella and Campylobacter in feedlot cattle.  On Day 0, cattle (n=288) at risk for bovine 
respiratory disease (BRD) were randomly assigned to either a non-treated, control pen (12 pens), 
or a fluoroquinolone (enrofloxacin; Baytril® 100) treated pen (12 pens).  Rectal fecal samples 
were collected from cattle on days 0, 7, 14, 21, and 28. Feces were cultured for Salmonella 
enterica and Campylobacter spp. using enrichment and selective isolation methods, and 
confirmed by serology and PCR. Susceptibilities to nalidixic acid and ciprofloxacin were 
determined using microbroth dilution methods. Data analyses were performed using linear 
mixed-models.  Overall, Salmonella and Campylobacter were recovered from 10.2% (139/1,364) 
and 12.4% (170/1,364) of the fecal samples, respectively. Campylobacter species included 
hyointestinalis, jejuni and coli.  Neither Salmonella nor Campylobacter prevalence were 
significantly impacted by fluoroquinolone treatment (P = 0.80, P = 0.61, respectively). However, 
Salmonella prevalence differed between study weeks (P < 0.01) with prevalence decreasing over 
time.  Prior to treatment, 98.9% (91/92) of Salmonella isolates were susceptible to nalidixic acid 
and ciprofloxacin. All Salmonella recovered post-treatment were susceptible to both 
antimicrobials (n=43). The majority of Campylobacter recovered prior to treatment were 
resistant to nalidixic acid (23/35; 65.7%) and ciprofloxacin (21/35; 60.0%). There were no 
significant treatment by week interaction (P = 0.85) or treatment effects (P = 0.61) on the post-
treatment prevalence of Campylobacter resistance. There was, however, a significant week effect 
(P = 0.05), with Campylobacter resistance prevalence decreasing over time.  In this 28-day 
study, we found no evidence that a fluoroquinolone used for metaphylaxis significantly impacts 
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fecal prevalence of Salmonella or Campylobacter or the fecal prevalence of nalidixic acid or 
ciprofloxacin resistance.    
Key words: fluoroquinolone; cattle; susceptibility; resistance; prevalence; Salmonella, 
Campylobacter 
 Introduction 
  Salmonella and Campylobacter are two of the most common causes of bacterial 
foodborne illness in humans (CDC, 1999). These bacteria are commensal gut flora in healthy, 
beef cattle and are typically shed in their feces (Kunze et al., 2008).  The United States 
Foodborne Diseases Active Surveillance Network (FoodNet) indicates that 1 million cases of 
salmonellosis and 1.3 million cases of campylobacteriosis are reported each year (CDC, 2014; 
CDC, 2015). Illness is often associated with the consumption of unpasteurized dairy products, 
raw or undercooked meat, and contaminated produce and water (CDC, 2014; CDC, 2015). 
Although few human illness cases are directly attributable to beef cattle, cattle may serve as a 
reservoir for both Salmonella and Campylobacter. 
 Human pathogenic organisms, such as Salmonella and Campylobacter, often carry 
antimicrobial resistance genes (Luo et al., 2003; Chen et al., 2007).  As antimicrobial resistance 
continues to become one of the biggest human health threats around the world, the use of 
antimicrobials in livestock has become highly scrutinized (Jan et al., 2012; Page and Gautier, 
2012). This is particularly true for medically important antimicrobials such as fluoroquinolones, 
which are used to treat both human and animal diseases (Jan et al., 2012; Page and Gautier, 
2012). However, there are minimal data that can be used to estimate the risk to humans 
associated with the use of fluoroquinolones or other antimicrobials in feedlot cattle.  
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 In the beef industry, the metaphylactic use of antimicrobials is an important tool for 
reducing bovine respiratory disease (BRD), the most common cause of morbidity and mortality 
(Bateman et al., 1990; Edwards 2010).  Metaphylaxis involves treating a group of cattle with a 
US Food and Drug Administration (FDA)-approved antimicrobial with the intent of controlling 
the incidence of acute onset BRD in high risk cattle (Ives and Richeson, 2015). To date, there is 
no evidence that the metaphylactic use of a fluoroquinolone has a negative impact on human 
health. Prevalence of quinolone resistance in retail ground beef has been very low over the past 
decade for both Salmonella and Campylobacter (FDA, 2015). However, the continued judicious 
use of fluoroquinolones in cattle and monitoring of resistant organisms that may be pathogenic to 
humans seems warranted. To our knowledge, there are no published data assessing whether 
metaphylaxis with a fluoroquinolone, such as enrofloxacin, has any impact on fecal shedding of 
Salmonella or Campylobacter in feedlot cattle. Therefore, the objective of this study was to 
assess the effect of using the fluoroquinolone, enrofloxacin, for metaphylaxis on the fecal 
prevalence of Salmonella and Campylobacter and the fecal prevalence of quinolone-resistant 
Salmonella and Campylobacter in feedlot cattle.     
 
 Materials and Methods 
  Study design 
 Two-hundred and ninety-eight, eight-month old, cross-bred beef calves were purchased 
from a livestock auction in Iowa and transported to a Kansas cattle feeder two days prior to study 
initiation. To be eligible for this study, calves were required to have had 1) no previous history of 
fluoroquinolone use, 2) no overt clinical signs of illness at arrival, and 3) been considered at high 
risk for BRD. High risk cattle are typically those with one or more risk factors for BRD, which 
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may include: auction market sourced, unknown vaccination or preconditioning status, recent 
weaning, transportation from multiple farm origins, an extended transport time with few to no 
rest stops, experience a, or exposure to dramatic temperature change of ≥ 30 °F from the origin 
to the study site, a ≥ 30 °F fluctuation in environmental temperature at a study site within a 24-
hour period, exposure to changes, or wet or cold weather conditions (Ives and Richeson, 2015; 
Bayer Healthcare, LLC, 2012).     
 Cattle were individually assigned a unique identification number, which appeared on 
duplicate ear tags and administered a modified-live vaccine (Bovi-Shield Gold®5; Zoetis, 
Kalamazoo, MI) and a parasiticide (Dectomax®; Zoetis, Kalamazoo, MI) during processing. 
Cattle were commingled across all truck loads in a large open feedlot pen and managed 
according to the feedlot’s standard management practices, until study initiation. 
 Prior to study initiation, 24 pens, arranged in a circular-fashion, were randomly assigned 
to a treatment group. A coin toss determined that the first study pen was assigned to treatment A 
and the second was assigned to treatment B.  Remaining pens were systematically assigned to 
treatments, so that every other pen was assigned to the opposite treatment.  Using the random 
number function in Excel® 2010 (Microsoft, Redmond, WA), animal ID numbers were then 
randomly assigned to a pen. The total number of pens, animals per pen, and samples per animal 
over time for each treatment group were determined via simulation methods in order to detect a 
relative difference of 50% between treatment groups over time in the pen-level mean resistance 
prevalence, with type 1 and type 2 errors < 0.05 and 0.2, respectively.   
 On study day 0, cattle were run through the chute and administered either a single, 
subcutaneous, 7.5 mg/kg dose of Baytril ®100 (Bayer Animal Health, Shawnee, KS; treatment 
A) (n=144; 12 pens; 12 calves per pen) or no drug (treatment B) (n=144; 12 pens; 12 calves per 
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pen), according to their randomized pen assignment; hereafter, groups referred to as treated and 
control pens, respectively.  Body weights were measured prior to treatment to ensure cattle were 
properly dosed. Once cattle were assigned to a pen and treatment was administered, cattle were 
placed in their respective pens where they were housed for the duration of the study (30 days).     
    Cattle health and performance 
 Routine health observations were conducted daily by the feedlot veterinarian.  Cattle that 
required therapy for non-infectious conditions (e.g., bloat, injury) and did not require an 
antimicrobial were treated as per the standard site protocol and placed back into their study pen. 
Cattle that required antimicrobial therapy for any reason, based on the veterinarian’s assessment 
(blinded to treatment group), were removed from the study pen. Once calves were removed from 
study pens, they were no longer considered part of the study.  
 Calves were fed a starter ration comprised of wet distiller’s grain and grass hay.  
Monensin (Rumensin®; Elanco Animal Health, Indianapolis, IN) was mixed in the ration, per 
label, to prevent coccidiosis. No tetracyclines, macrolides, or other antimicrobials were included 
in the feed. Body weights were measured for all cattle on study day 0 and the last day of the 
study (study day 30).  If cattle were removed from the study, their body weights were measured 
the day they were removed.   
  Sample collection 
 Individual fecal samples (approximately 20 g) were collected from the rectum of all study 
cattle on study days: 0, 7, 14, 21 and 28 (+/- 2 days). Samples were placed in Whirlpak bags 
(Nasco, Inc., Fort Atkinson, WI) pre-labeled with the animal ID, study day, and date of 
sampling. Samples were transported immediately on ice to the Kansas State University pre-
harvest food safety laboratory for same-day processing and analysis.        
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  Salmonella isolation 
 Ten grams of feces were suspended in 90 mL Tetrathionate (TT) broth (Becton, 
Dickinson Co., Sparks, MD) and incubated at 37°C for 24 h. After incubation, 100 µL of the 
suspension was transferred to 10 mL Rappaport-Vassiliadis (RV) broth (Becton, Dickinson Co.) 
and incubated at 42°C for 24 h. Enriched samples were then streaked on Hektoen Enteric (HE) 
agar plates (Becton, Dickinson Co.) and incubated at 37°C for 24 h. Three colonies with 
morphology similar to Salmonella (blue-green colony with black centers) for each sample were 
streaked onto blood agar (Remel, Lenexa, KS) and incubated at 37°C for 24 h. A single colony 
was tested by slide agglutination with polyvalent O antisera for Salmonella serogroups B, C1, 
C2, D1, D2 and E. Isolates that agglutinated with the polyvalent O antisera were considered 
Salmonella.  Confirmed isolates were stored in cryo-protection beads (Hardy Diagnostics, Santa 
Maria, CA) at -80°C. 
  Campylobacter isolation 
 Campylobacter was isolated from feces using a method described by Burrough and others 
(2013). Briefly, fecal samples were suspended at a ratio of 1:10 (1 g feces to 9 mL broth) in 
Mueller-Hinton (MH) broth (Becton Dickinson Co., Sparks, MD) containing selective 
(polymyxin B, rifampicin, trimethoprim, and cycloheximide; Oxoid, Campbridge, UK) and 
growth supplements (SS; sodium pyruvate, sodium metabisulfite and ferrous sulfate; Oxoid) and 
incubated under microaerophilic conditions (5% Oxygen, 10% Carbon Dioxide and 85% 
Nitrogen) at 42°C for 48 h. The enrichment culture was streaked for isolation onto MH+SS agar 
(Becton Dickinson) and incubated under microaerophilic conditions for 48 h at 42°C. Plates 
were observed for Campylobacter growth and three, well-isolated colonies per sample were 
streaked onto MH agar. Plates were incubated at 37°C for 24-30 h under microaerophilic 
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conditions. Pure cultures were then transferred from each agar plate to separate cryovials 
containing MH broth with 30% glycerol (Fisher, Fair Lawn, NJ). Vials were stored at -80°C until 
genus confirmation and species identification were performed. 
  Campylobacter confirmation and speciation 
 Presumptive Campylobacter colonies were removed from the freezer (- 80°C) and 
streaked for isolation onto MH+SS agar plates. Plates were incubated under microaerophilic 
conditions at 42°C for 48 h. Approximately 2-3 colonies were transferred to single cell lysis 
buffer (1 ml Tris-EDTA (1x TE) + 10 µl proteinase K (5 mg/ml)) for DNA extraction (Olah, et 
al., 2006).  A multiplex PCR assay (Yamazaki-Matsune et al., 2007) that identifies six species of 
Campylobacter (jejuni, coli, lari, fetus, upsaliensis and hyointestinalis subsp. hyointestinalis) 
was used.  Campylobacter jejuni ATCC 33560, Campylobacter coli NCTC 36572, 
Campylobacter lari ATCC 35222, Campylobacter fetus subsp. fetus ATCC 27374, 
Campylobacter upsaliensis ATCC 49815 and Campylobacter hyointestinalis subsp. 
hyointestinalis ATCC 35217 were used as positive controls.  
  Susceptibility testing of Salmonella isolates 
 The Clinical and Laboratory Standards Institute’s (CLSI) micro-broth dilution methods 
were used to determine minimum inhibitory concentrations of nalidixic acid and ciprofloxacin 
for all Salmonella isolates tested (CLSI, 2008). Susceptibility testing was performed on one 
Salmonella isolate per fecal sample. Stock solutions of nalidixic acid and ciprofloxacin (Sigma-
Aldrich, St. Louis, MO) were prepared in sterile, distilled water at a concentration of 1 mg/mL 
based on the potency of the antimicrobial. Isolates were tested at concentrations of 100, 50, 25, 
12.5, 6.25, 3.125, 1.56, 0.78, 0.39 and 0.195 µg/mL for nalidixic acid and 6.25, 3.125, 1.56, 0.78, 
0.39, 0.195, 0.098, 0.049, 0.024, and 0.012 µg/mL for ciprofloxacin.  
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 The inoculum was prepared by selecting a single colony from a blood agar plate (Remel) 
and mixing it with 10 mL Mueller Hinton II broth (Becton–Dickinson, Sparks, MD). The 
inoculum was incubated for 6 h and the cell turbidity was adjusted to 0.5 McFarland turbidity 
standard. The culture was diluted (1:100) in Mueller-Hinton broth II for an inoculum of 5×105 
cfu/ml. A 96-well plate was used to perform the antimicrobial susceptibility test for each 
antimicrobial and plates were incubated for 24 h at 37°C.  Escherichia coli (ATCC 25922) was 
used as a positive control. Isolates were tested in quadruplicate and results were recorded as 
either “growth” or “no growth” for each well.  
 The minimum inhibitory concentration (MIC) was the lowest concentration of 
antimicrobial agent that inhibited the growth of the organism. Salmonella isolates were 
considered susceptible to nalidixic acid if the MIC was ≤ 16 µg/mL and ≤ 0.06 µg/mL for 
ciprofloxacin. Isolates were considered resistant if the MIC was ≥ 32 µg/mL or  ≥ 1 µg/mL, for 
nalidixic acid and ciprofloxacin, respectively (CLSI, 2013).  Further testing was performed for 
Salmonella isolates considered resistant using Sensititre® plates that contained 17 antimicrobials 
and a semi-automated testing system (Sensititre; TREK Diagnostics, Westlake, OH). Isolates 
determined to be resistant by microbroth dilution were submitted to the National Veterinary 
Services Laboratory (NVSL; Ames, IA) for serotyping. 
  Susceptibility testing of Campylobacter isolates 
 One Campylobacter isolate per fecal sample was tested using the micro-broth dilution 
method as described above at concentrations of nalidixic acid of 100, 50, 25, 12.5, 6.25, 3.125, 
1.56, 0.78, 0.39 and 0.195 µg/mL and concentrations of ciprofloxacin at 25, 12.5, 6.25, 3.152, 
1.56, 0.78, 0.39, 0.195, 0.098 and 0.049µg/mL.  Inoculum was prepared for each isolate by 
streaking pure culture onto MH+SS agar and incubating each plate under microaerophilic 
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conditions for 48 h at 37°C. One isolate from each plate was transferred to MH agar (without 
supplements) and incubated for 24-30 h at 42°C. Using a sterile, disposable swab, pure culture 
was transferred to 3 mL MH II broth. The inoculum was adjusted using a spectrophotometer (OD 
600) and MH II broth, so that the inoculum was equivalent to 0.5 McFarland standard. The final 
inoculum was prepared at a 1:100 dilution using MH II broth with 2.5% lysed horse blood.  
 Antimicrobial susceptibilities were performed using 96-well microtiter plates (Becton 
and Dickinson, Franklin Lakes, NJ) and a quality control organism, Campylobacter jejuni ATCC 
33560, which was used as a positive control. Plates were covered using perforated plate covers 
and incubated under microaerophilic conditions at 37°C for 48 h. Isolates were tested in 
quadruplicate and considered susceptible if the MIC was ≤ 16 for nalidixic acid or ≤ 1 for 
ciprofloxacin.  Campylobacter isolates were considered resistant if the MIC was ≥ 64 µg/mL for 
nalidixic acid or ≥ 4 µg/mL for ciprofloxacin (NARMS, 2011).    
  Statistical Analyses 
The number of pens used in this study was determined based on an alpha of 0.05, a 
statistical power of 0.80 and a presumed delta of 50%. Twelve pens per treatment group, with 12 
cattle per pen, were found to be sufficient in finding a significant difference in the proportion of 
antimicrobial resistance between the two treatment groups.   
The proportion of fecal samples that tested positive for Salmonella or Campylobacter 
within each pen on each sampling day was determined. A sample was considered positive if at 
least one isolate was obtained from an individual fecal sample. Differences in the pen-level 
prevalence of Salmonella and Campylobacter between treatment groups were evaluated using 
generalized linear mixed models, which were fitted using a binomial distribution, maximum 
likelihood estimation, complimentary-log-log link, Kenward-Roger degrees of freedom and 
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Newton-Raphson and Ridging optimization procedures (Proc GLIMMIX SAS 9.3, SAS Institute, 
Inc., Cary, NC). The outcome variable was the number of Salmonella or Campylobacter test 
positive samples in a pen (events)/number of samples collected per pen (trials), for each 
sampling week. Treatment (metaphylaxis yes/no), week (n=4), treatment by week interaction and 
a variable representing the baseline prevalence on study day 0 (prior to antimicrobial 
administration) for each pen were included in the model as independent variables. A random 
effect, using an autoregressive covariate structure, was used to account for the lack of 
independence of repeated measures in pens over time.    
Descriptive statistics were used to evaluate the MIC data for both nalidixic acid and 
ciprofloxacin for Salmonella and Campylobacter isolates recovered during this study.  Since all 
confirmed isolates were tested in quadruplicate, the mode MIC value was reported for each 
sample. When only two MIC values were available, the MIC value with the highest 
concentration was used.  If MIC values varied for all four plates, the isolate was re-tested and 
either the mode or the highest MIC value was reported. 
Based on the susceptibility results, proportions of Salmonella or Campylobacter isolates 
resistant to either nalidixic acid or ciprofloxacin for each pen, for each sampling week, were 
determined. Differences in pen-level (nalidixic acid or ciprofloxacin) resistance prevalence 
estimates, for both Salmonella and Campylobacter were evaluated for the treatment groups using 
generalized linear mixed models as described above. The outcome variable was the number of 
resistant isolates per pen/the number of samples collected per pen for each sampling week. 
Similar to prevalence, treatment (metaphylaxis yes/no), week (n=4), treatment by week 
interaction and a variable representing the baseline prevalence on study day 0 (prior to drug 
administration) for each pen were included in the model as independent variables. A goodness of 
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fit test was used to examine overall model fit and Pearson and Deviance residuals were used to 
evaluate potential outliers and influential observations at the pen-level.   
Average daily gain (ADG; pen-level) was calculated for both treatment groups by 
subtracting the weight of the cattle within each pen on study day 0 from the their weight on study 
day 30 and dividing it by the number of days the cattle were in the study.  Average daily gain 
was calculated with and without cattle that died or were euthanized.  The proportion of moribund 
cattle that were removed from the study pens due to BRD, as well as the number of deaths due to 
BRD, were calculated and summarized. Cattle performance and health data were analyzed with 
general and generalized linear mixed models, respectively, for normal and binomial distributions 
(as described above). 
 Results 
  Baseline Body Weights and Fecal Shedding of Salmonella and Campylobacter 
 On the day of enrollment, mean body weights of cattle were not significantly different 
between treatment groups (Table 1). Baseline prevalence of Salmonella was numerically higher 
in cattle assigned to a treated pen (35.4%) compared to cattle assigned to a control pen (29.2%), 
but this difference was not statistically significant (Table 1). The majority of Salmonella isolates 
belonged to serogroup B (87.1%; 81/93), followed by serogroup E (4.3%; 4/93), serogroup A 
(2.2%; 2/93) and serogroup C1 (2.2%; 2/93).  Four isolates did not test positive for any of the six 
serogroups evaluated.  Susceptibility results revealed that 98.9% (91/92) of the Salmonella 
isolates recovered prior to treatment were susceptible to both nalidixic acid and ciprofloxacin. 
The MIC of the isolate resistant to nalidixic acid was ≥ 32 µg/mL and was identified as serotype 
Agona. The isolate was tested against 17 human antimicrobials (amoxicillin/clavulanic acid, 
ampicillin, azithromycin, cefoxitin, ceftiofur, ceftriaxone, chloramphenicol, ciprofloxacin, 
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gentamicin, kanamycin, nalidixic acid, streptomycin, sulfisoxazole, tetracycline, and 
trimethoprim/sulphamethoxazole) and was resistant to all antimicrobials except for 
ciprofloxacin, gentamicin, and kanamycin.  
 Baseline prevalence of Campylobacter (prior to antimicrobial administration) tended to 
be higher in cattle randomly assigned to a treated pen compared to cattle assigned to a control 
pen (Table 1). The majority of the isolates across both treatment groups were C. coli (20/35; 
57.1%), followed by C. jejuni (13/35; 37.1%) and C. hyointestinalis (2/35; 5.7%). The recovery 
of C. coli from the feces of enrolled cattle was significantly higher (P = 0.04) in cattle assigned 
to a treated pen (10.4%; 15/144) compared to a control pen (3.5%; 5/144) prior to treatment 
administration. No difference was found for C. jejuni or C. hyointestinalis (P > 0.05).   
 Most Campylobacter isolates recovered prior to treatment were resistant to nalidixic acid 
(23/35; 65.7%) and ciprofloxacin (21/35; 60.0%).  Of those nalidixic acid-resistant isolates, 
73.9% (17/23) were from cattle assigned to a treated pen and 26.1% (6/23) were from cattle 
assigned to a control pen. For ciprofloxacin resistant isolates, 71.4% (15/21) were from the feces 
of cattle assigned to treated pens and 28.6% (6/21) were from the feces of cattle assigned to 
control pens. Mean pen-level (nalidixic acid) resistance prevalence, prior to treatment, was 
significantly higher for cattle assigned to treated pens (11.8%) when compared to cattle assigned 
to control pens (4.2%; P = 0.03) and also tended to be different for ciprofloxacin (P = 0.06) for 
treated pens (10.4%) versus control pens (4.2%), despite the fact that all of these samples were 
collected prior to treatment administration.      
  Post-Antimicrobial Administration - Salmonella Prevalence 
 Overall sample-level prevalence of Salmonella across both treatment groups, post-
treatment, was 4.3% (46/1076). Salmonella prevalence did not differ significantly between the 
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treated versus the control pens of cattle (P = 0.80; Figure 1). The treatment by week interaction 
was not statistically significant (P = 0.41), however, prevalence did vary by study week (P < 
0.01), with Salmonella prevalence decreasing over time for both treatment groups. The majority 
of the Salmonella isolates recovered, post-treatment, belonged to serogroup B (67.4%; 31/46), 
followed by serogroup E (8.7%: 4/46) and serogroup C1 (4.3%; 2/46).  Nine isolates did not test 
positive for any of the six serogroups tested.   
  Post-Antimicrobial Administration - Salmonella Susceptibility  
 Of the 46 isolates confirmed to be positive for Salmonella, 43 (93.5%) were viable and 
tested. All isolates tested were susceptible to both nalidixic acid (MIC ≤ 16 µg/mL) and 
ciprofloxacin (MIC ≤ 0.06 µg/mL). Most of the isolates had a MIC of 6.25 µg/mL (83.7%; 
36/43) for nalidixic acid and a MIC of 0.024 µg/mL for ciprofloxacin (74.4%; 32/43). No isolate 
was above the breakpoint for either antimicrobial tested.    
  Post-Drug Administration - Campylobacter Prevalence  
 Overall Campylobacter sample-level prevalence across all study pens, post-treatment was 
12.5% (135/1076). There was no significant difference (P = 0.65) in Campylobacter prevalence 
in pens of cattle treated with enrofloxacin compared to the non-treated, control pens (Figure 2). 
There was no significant treatment by week interaction (P = 0.62), nor was there a significant 
difference by study week (P = 0.10). 
 Of the Campylobacter isolates recovered, C. coli accounted for 78.5% (106/135) of the 
isolates and C. jejuni accounted for 21.5% (29/135) of the isolates.  Model-adjusted pen-level 
prevalence of C. coli was significantly higher in treated pens when compared to the control pens 
(P = 0.04). There was no significant treatment by week interaction (P = 0.88), though there was a 
significant week effect (P < 0.01).  Mean C. jejuni prevalence was not significantly different (P 
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= 0.70) in the treated pens compared to the control pens of cattle, nor was there a significant 
treatment by week interaction (P = 0.80) or a week effect (P = 0.07), post-treatment.   
  Post-Antimicrobial Administration - Campylobacter Susceptibility 
 All 135 Campylobacter isolates obtained post-treatment were viable and subjected to 
susceptibility testing. Nalidixic acid and ciprofloxacin MICs for these isolates ranged from 1.56 
µg/mL to ≥ 100 µg/mL for nalidixic acid and 0.049 µg/mL to ≥ 6.25 µg/mL for ciprofloxacin.  
Of the isolates tested, 81.5% (110/135) were resistant to both nalidixic acid (MIC ≥ 64 µg/mL) 
and ciprofloxacin (MIC ≥ 4 µg/mL). One-hundred and four of these isolates were C. coli and the 
remaining 31 isolates were C. jejuni. There were significantly more C. coli 98.1% (102/104) than 
C. jejuni 28.1% (8/31) isolates resistant to both antimicrobials (P < 0.01).  All other isolates 
(18.5%; 25/135) were susceptible to both antimicrobials (i.e., there were no isolates resistant to 
just one drug). 
 Pen-level prevalence of resistant Campylobacter did not differ significantly (P = 0.61) 
between the treated and control pens for either drug tested (Figure 3), and there was no evidence 
of a significant treatment by study week interaction (P = 0.85). There was, however, a significant 
week effect as the mean prevalence of resistant Campylobacter isolates decreased over time for 
both treatment groups (P = 0.05).  
  Cattle Health and Performance 
 Within the four weeks post-treatment, 10 clinically ill cattle were removed from the 
treated pens and 17 cattle were removed from the control pens. All cattle were removed due to 
clinical signs of BRD, with the exception of two cattle that were removed from control pens due 
to lameness. The BRD morbidity was not significantly different among treatment groups (Table 
2). Three mortalities occurred during this study (1 from treated, 2 from control pens).  Necropsy 
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results indicated that all deaths were attributable to BRD.  There was a statistically significant 
difference in mean ADG for cattle in the treated and control pens (Table 2).  However, when 
cattle that died were removed from the weight gain analysis, the ADG means were not 
significantly different (Table 2).           
 Discussion  
 This study demonstrated no evidence that enrofloxacin metaphylaxis impacts the 
prevalence of Salmonella and Campylobacter in the feces of feedlot cattle, or the prevalence of 
resistance of these organisms to nalidixic acid or ciprofloxacin.  Although not associated with 
treatment group, the overall prevalence of quinolone resistance in Campylobacter, particularly C. 
coli, was quite high (over 80% during the study period).  In contrast, the overall prevalence of 
Salmonella resistance to nalidixic acid or ciprofloxacin was very low (0% during the study 
period). Although the epidemiology and risk factors for antimicrobial resistance in 
Campylobacter and Salmonella in feedlot cattle must be further investigated, based on this study, 
there is no evidence that enrofloxacin metaphylaxis is a significant driver of the prevalence and 
susceptibility of these organisms.   
 Considering the study season, location and cattle type, prevalence of Salmonella and 
Campylobacter in cattle during enrollment was consistent with other reports (Galland et al., 
2000; Kunze et al., 2008; Sanad et al., 2011). Salmonella prevalence did not differ significantly 
when comparing treated to non-treated pens of cattle. These findings were similar to results 
reported from a previous study where the number of fluoroquinolone treatments administered to 
cattle at five commercial feedlots was not associated with Salmonella prevalence (Smith et al., 
2016).  Salmonella prevalence did, however, differ across study weeks with prevalence 
decreasing over time. It is possible that being exposed to other cattle at the sale barn, the stress of 
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being transported to the research site, as well as acclimation to a new diet and environment had 
an impact on overall prevalence of Salmonella.  Research has shown that the transportation of 
cattle can be a potential stressor for the increased shedding of Salmonella spp. (Barham et al., 
2002). Type of diet has also been shown to be associated with the culture-positive status of cattle 
tested for Salmonella (Green et al., 2010). With prevalence in the current study being 3 to 4 
times higher at study initiation than at the end of the study, it seems plausible that initial 
production or transportation stresses affected the prevalence of Salmonella fecal shedding over 
time.  
On the day of enrollment, prevalence of Salmonella resistance was low, which was 
expected given that cattle had no history of previous exposure to a fluoroquinolone (inclusion 
criteria). The low prevalence of quinolone-resistant Salmonella isolated from cattle is consistent 
with the literature (Beach et al., 2002; FDA, 2015). The single Salmonella isolate that was 
resistant to nalidixic acid prior to treatment was also found to be multidrug-resistant (14 human 
antimicrobials).  It is not unusual for Salmonella isolates from beef cattle to be either pan-
susceptible or resistant to multiple antimicrobials (Dargatz et al., 2000; Khaitsa et al., 2007; 
Krueger et al., 2014).    
 All Salmonella isolates recovered, post-treatment, were susceptible to both nalidixic acid 
and ciprofloxacin, with MICs well below the breakpoint for both antimicrobials. These results 
are consistent with other research, where the isolation of quinolone-resistant Salmonella from 
beef cattle was either low or not detected (Dargatz et al., 2000; Beach et al., 2002; Kunze et al., 
2008). Fluoroquinolone metaphylaxis did not significantly affect prevalence of resistant 
organisms isolated from cattle feces in this study, which is consistent with a previous 
observational study where previous fluoroquinolone use for BRD treatment within pens of cattle 
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was not associated with the susceptibility of Salmonella to human quinolones (Smith et al., 
2016).   
 Data regarding the prevalence of Campylobacter isolated from US beef cattle are scarce. 
The current study showed that the prevalence of Campylobacter across study weeks was highly 
variable for cattle in both the treated and non-treated control pens and that metaphylaxis 
treatment with a fluoroquinolone was not associated with prevalence. As previously discussed 
for Salmonella sp., it is possible that acclimation to a new diet and environment may have 
contributed to the variability in Campylobacter spp. prevalence (Sproston et al., 2011). 
Campylobacter jejuni is reported as the most prevalent Campylobacter species isolated from 
cattle and is the most common cause of human campylobacteriosis in the U.S. (Altekruse et al. 
1999; Englen et al. 2005; FDA, 2014; Gaudreau et al. 2014). However, prevalence of C. jejuni in 
this study was fairly low and accounted for less than 25% of the Campylobacter isolates 
recovered. The reason for low prevalence of this Campylobacter species in our cattle population 
is unknown.  Campylobacter coli was the most prevalent Campylobacter species isolated in this 
study, with significantly more C. coli isolates recovered from the treated pens of cattle compared 
to the control pens. Campylobacter coli are typically isolated from swine and poultry and tend to 
have higher antimicrobial resistance prevalence when compared to C. jejuni (Moore et al. 2006). 
A similar trend was noted in the current study with significantly more C. coli isolates showing 
resistance to both nalidixic acid and ciprofloxacin when compared to C. jejuni.  Campylobacter 
mutants found to be highly resistant to quinolone antimicrobials typically have a single-point 
mutation in the gyrA gene, which is part of the quinolone drug binding site (Luo et al. 2003).  
This single step mutation keeps quinolone antimicrobials from binding, causing clinically 
relevant levels of resistance to quinolone antimicrobials (Wang et al. 1993).  
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 Studies of the effects of fluoroquinolone treatment on the prevalence of fluoroquinolone-
resistant Campylobacter in swine and poultry have shown that resistance prevalence increases 
rapidly after treatment and persists for several days in both the animal and the environment 
(McDermott et al. 2002; Usui et al. 2014).  However, results from the current study showed that 
the mean Campylobacter resistance prevalence in cattle feces within a pen was not significantly 
impacted by fluoroquinolone use, and declined over time for both treatment groups to less than 
10% by the end of the 4 week study period. Assuming this decline reflects what is commonly 
found in commercial finishing feedlots after the Baytril® 28-day withdrawal time has been met, 
cattle should have minimal resistance prevalence at harvest. With the National Antimicrobial 
Resistance Monitoring System (NARMS) no longer reporting Campylobacter due to low 
prevalence of this organism in ground beef, this assumption is plausible (FDA, 2015).      
Prevalence of Campylobacter resistance at baseline (prior to drug administration) was 
rather high with > 60% of the isolates resistant to at least one of the antimicrobials tested. These 
results were unexpected, since cattle had no history of being administered a fluoroquinolone 
prior to enrollment. However, a similar finding was noted in a longitudinal study examining the 
prevalence of antimicrobial-resistant Campylobacter strains isolated from conventional and 
antibiotic-free swine (Quintana-Hayashi and Thakur, 2012a). Authors reported a high prevalence 
of multidrug-resistant (MDR) Campylobacter isolates obtained from antibiotic-free swine and 
their environment, with the majority of those isolates identified as C. coli.  In a follow-up study, 
researchers performed multilocus sequence typing (MLST) on the MDR C. coli isolates and 
found that pigs that did not carry MDR isolates at the farm, acquired the resistant strains at the 
slaughter plant (Quintana-Hayashi and Thakur, 2012b).  It is possible that cattle in the current 
study acquired resistant isolates either at the sale barn or during transit to the study site.  
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However, the time of acquisition of the resistant organisms could not be determined in the 
present study as the cattle were not sampled prior to arrival to the study site.   
 More than half of the cattle were shedding quinolone-resistant Campylobacter on the day 
of enrollment. As there were no data on resistance prevalence for these cattle prior to study 
initiation, it was not accounted for in the study design, and the resulting randomization process 
unfortunately resulted in a difference in the prevalence of animals shedding resistant organisms 
between treated and control pens.  While the statistical analysis of treatment effects accounted 
for the baseline prevalence, the large number of cattle shedding resistant Campylobacter prior to 
enrollment may have influenced the overall Campylobacter prevalence or resistance prevalence 
throughout the study.  As noted by Zhang et al. (2006), resistant isolates can have a fitness 
advantage compared to susceptible isolates, even in the absence of antimicrobial selection 
pressure. This may have influenced the overall resistance prevalence during the four week study 
period, even though resistance did not differ significantly between treatment groups (Figure 3).   
No significant differences were observed when evaluating the pen-level prevalence of 
quinolone-resistant Campylobacter isolates recovered from the feces of cattle administered 
fluoroquinolone metaphylaxis compared to non-treated cattle. Though MIC values were 
generally high throughout the study, they were consistently high for isolates recovered from both 
treatment groups. Adding monensin to the feed of both treatment groups may have influenced 
the overall resistance prevalence of Campylobacter spp.  However, ionophores have a different 
mode of action than fluoroquinolones, and bacteria typically adapt to ionophores rather than 
mutate or acquire resistance genes (Russell and Houlihan, 2003).  With C. coli being the most 
prevalent species isolated, an overall high prevalence of resistance to quinolones could be 
expected (Moore et al. 2006; Gaudreau et al. 2014).  
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Although cattle at high risk for BRD were purposely selected for this study, overall BRD 
morbidity and mortality throughout the study were relatively low. Only 8.7% (25/288) of the 
cattle enrolled in the study were removed due to clinical BRD, with no statistical differences 
detected between treatment groups. Since the impacts of treatment on cattle health was not one 
of our primary objectives, and thus sample size was not optimized for this outcome, making 
inferences based on these results could result in Type II error.  Data collected on BRD morbidity 
and mortality were merely recorded as an indicator of clinical disease and a descriptor of the 
cattle in the study population. The impact of BRD also can be reflected in performance measures 
such as ADG, as shown by Cusack et al. (2007). In the current study, ADG was significantly 
higher in the treated pens of cattle compared to the control pens when all cattle were included in 
the analysis, but those results were apparently driven by a disproportional number of mortalities 
in each group (Table 2).  Differences in cattle performance between cattle given metaphylaxis 
versus untreated controls were expected. Several studies have shown that the type and the timing 
of BRD treatment can impact cattle performance over time (Bateman et al., 1990; Babcock et al., 
2009 and 2010).  
 In conclusion, our results indicate that metaphylaxis administration of the 
fluoroquinolone enrofloxacin to beef cattle for the control of BRD did not affect prevalence and 
susceptibility of Salmonella and Campylobacter when compared to non-treated cattle.  A 
relatively large proportion of the cattle enrolled in this study were shedding Salmonella and 
Campylobacter prior to study initiation. Furthermore, a high percentage of the Campylobacter 
isolates recovered from the feces of these cattle were resistant to quinolones upon the start of the 
study, even though cattle were not previously exposed to a fluoroquinolone. Despite cattle 
harboring quinolone-resistant Campylobacter prior to enrollment, metaphylaxis use of a 
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fluoroquinolone did not increase the prevalence of resistance after administration, and in fact, the 
prevalence of resistance declined (in both treatment groups) throughout the study period.  
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Table 4-1: Model-adjusted mean body weight and pathogen prevalence in feces of cattle at 
the time of enrollment (pre-treatment) for cattle randomized to either the Baytril® 100 
treated pens, or the non-treated, control pens. 
 
Variable, (Unit) Treated pens Control pens P-valueb 
Animal (Pens) 144 (12) 144 (12) - 
Arrival Body Weight (kg)   0.98 
Meana 271.5 271.4  
95% Confidence Interval 266.2 – 276.8 266.1 – 276.7  
Salmonella Prevalence (%)   0.27 
Meana 35.4 29.2  
95% Confidence Interval 27.7 – 44.0 22.0 – 37.6  
Campylobacter Prevalence (%)   0.06 
Meana 16.0 8.33  
95% Confidence Interval 10.6 – 23.4 4.6 – 14.5  
 aModel-adjusted means 
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Figure 4-1: Model-adjusted mean pen-level Salmonella prevalence (and 95% confidence 
intervals) by week post-treatment, for cattle in Baytril® 100 metaphylaxis treated and non-
treated, control groups.  There was no significant interaction between time and treatment 
group, or a significant difference between treatment groups, but prevalence across both 
groups differed over time.   
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Figure 4-2: Model-adjusted mean pen-level Campylobacter prevalence (and 95% confidence 
intervals) by week post-treatment, cattle in Baytril® 100 metaphylaxis treated and non-
treated, control groups.  There was no significant interaction between time and treatment 
group, or significant differences between treatment groups or among weeks. 
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Table 4-2: Bovine respiratory disease (BRD) and average daily weight gain (ADG) as 
primary health and performance outcomes for cattle randomized to either Baytril® 100 
metaphylaxis treated pens or a non-treated, control pens. 
 
Variable, (Unit) Treated pens Control pens P-value 
Animal (Pens) 144 (12) 144 (12) - 
BRD morbidity (%)   0.31 
                                               Meana 6.94 10.4  
                  95% Confidence Interval 3.6 – 12.8 6.20 – 17.0  
BRD mortality (%)   0.58 
Meana 0.69 1.39  
95% Confidence Interval 0.1 -  5.3 0.3 - 5.8  
ADG (Deads in) (kg)   0.05 
Meana 1.4 1.2  
95% Confidence Interval 1.3 - 1.5 1.1 - 1.3  
ADG (Deads out) (kg)   0.07 
Meana 1.4 1.3  
95% Confidence Interval 1.3 - 1.5 1.2 - 1.4  
 aModel-adjusted means 
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Chapter 5 - Conclusion 
 For over 90 years, antimicrobials have been indispensable tools for decreasing both 
morbidity and mortality associated with human and animal infectious diseases. They continue to 
remain effective against most infectious agents, yet prolonged, intense, and sometimes 
inappropriate use has led to the emergence of multiple antibiotic-resistant, zoonotic bacterial 
pathogens. Because of this, several U.S. and global agencies, along with the scientific 
community around the world, are working to assess the effects of using antimicrobials in food 
animals.  The result of this collaboration contributes data needed to assure that the public health 
is protected and that animal health needs are being met. 
 Data presented in the previous three chapters will aid in the continued effort to better 
understand the outcomes associated with the judicious use of antimicrobials in the beef cattle 
industry. Judicious use of therapeutic antimicrobials is an approach defined by the U.S. Food and 
Drug Administration (FDA) as a way to “maximize therapeutic efficacy and minimize the 
selection of resistant microorganisms” (FDA, 2016). Administration of antimicrobials to food 
animals at low concentrations has been shown to increase weight gain and reduce the spread of 
stress-associated diseases (Butaye et. al, 2003). Though there are few studies that show a true 
link between the number of antimicrobials administered to livestock and the increased 
prevalence of resistant pathogenic organisms shed by those animals, this practice has been 
labeled as a potential driver for the emergence of resistant microorganisms.  
 In 2013, the FDA released a guidance document that provided recommendations for 
medically important antimicrobial drug use in veterinary medicine (FDA, 2013). This document 
states that the FDA promotes the use of antimicrobials as therapy, control and prevention of 
diseases in animals; however, it also states that the U.S. government will no longer approve the 
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use of antimicrobials as a means of “increasing weight gain” or “improving feed efficiency.” 
Veterinary oversight is recommended for all approved drugs, and the microbiological effects on 
bacteria of human health concern should be evaluated for all new animal drugs, especially drugs 
that are critically important to human health (FDA, 2013).   
 As previously stated, fluoroquinolones are broad-spectrum antibiotics that play an 
important role in treating serious infections in humans. Fluoroquinolones are also used to treat 
bovine respiratory disease in cattle. Because this drug plays such a critical role in both human 
and animal medicine, the continued effort to evaluate its use was deemed necessary.  
 Evaluating the prevalence and quinolone resistance prevalence of the human enteric 
pathogens, Salmonella and Campylobacter, in beef cattle administered a fluoroquinolone for the 
treatment of bovine respiratory disease (BRD), was a way of assessing the impact of judicious 
use of this critically important drug. Our studies indicated that the use of a fluoroquinolone in 
feeder cattle was not associated with the pen-level prevalence of Salmonella and Campylobacter, 
nor was it associated with nalidixic acid and ciprofloxacin resistance prevalence for either 
organism. In the observational study, the number of fluoroquinolone treatments administered 
within each pen for BRD treatment was not significantly associated with the prevalence or 
resistance prevalence of Salmonella and Campylobacter, nor was it associated with factors such 
as metaphylaxis use (with any drug) or gender. In the randomized clinical trial, metaphylactic 
use of a fluoroquinolone in high risk pens of cattle did not significantly increase prevalence or 
quinolone resistance prevalence when compared to untreated pens of cattle, nor did it 
significantly alter the quinolone susceptibilities of Salmonella or Campylobacter isolated from 
cattle within each pen.  
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 Prevalence of Salmonella isolated from the feces of cattle for both studies was fairly low 
(38% for Trial #1 and 4.3% for Trial #2), and quinolone-resistance prevalence was negligible, 
with only two isolates resistant to nalidixic acid. Campylobacter prevalence was slightly higher 
in fecal samples collected for the observational study (27.2%) compared to the randomized 
clinical trial (12.5%).  It was fairly common for Campylobacter isolates to be resistant to 
nalidixic acid and ciprofloxacin for both studies, particularly if the isolate was C. coli. Greater 
than 60% of the Campylobacter isolated from the feces of cattle with no known exposure to a 
fluoroquinolone were resistant to both human quinolones. With cattle being a major reservoir of 
this zoonotic pathogen, continued monitoring of the development of quinolone-resistant 
Campylobacter in cattle is necessary to reduce the human food safety risk.   
  As we continue to monitor medically important antimicrobial drug use in food-producing 
animals, efforts are being made by both veterinarians and human physicians to help mitigate the 
antimicrobial resistance dilemma. Antimicrobial alternatives such as: antibacterial vaccines, 
immunomodulators, bacteriophages and the use of edolysins and antimicrobial peptides are all 
being examined for their ability to reduce pathogenic organisms in humans and animals (Cheng 
et al., 2014). Prebiotics and probiotics are currently being used in livestock to enhance the 
gastrointestinal microbial environment and to out-compete the pathogenic microorganisms for 
both space and nutrients (Uyeno et al., 2015). Human medical doctors, as well as veterinarians, 
are culturing pathogens whenever possible to make sure the appropriate therapy is administered, 
and patients are being advised to complete the full course of therapy when an antimicrobial is 
prescribed (Madigan, 2006). Increased efforts are being made to preserve the efficacy of our 
current human antimicrobial therapy and at the same time promote the continued judicious use of 
antimicrobial drugs in our animal production system.    
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 Future research is still needed, however, to further explore the antimicrobial resistance 
mechanisms used by pathogenic organisms, to explore the risk factors associated with the 
transmission of these resistant pathogens and to develop intervention strategies to keep 
antimicrobial resistance at a minimum.   Further investigation will facilitate the development of 
strategies to maintain and improve antimicrobial use in animal health, while addressing 
antimicrobial resistance concerns related to human health.              
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